{
  "dataset": "sprint",
  "total_mechanisms_analyzed": 15,
  "total_abstracts_retrieved": 221,
  "overall_support_count": 29,
  "overall_conflict_count": 7,
  "overall_neutral_count": 185,
  "mechanism_results": [
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "With aging, arterial stiffness increases, which can alter hemodynamic responses to blood pressure changes.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND (age OR elderly OR geriatric) AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"hemodynamic\" OR \"stiffness\" OR \"increases\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 7,
      "conflict_count": 0,
      "neutral_count": 13,
      "support_percentage": 35.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.35,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses risk factors and pathophysiology of atrial fibrillation, including age and high blood pressure, but does not mention arterial stiffness, age-related changes in arterial stiffness, or altered hemodynamic responses to blood pressure changes. Therefore it neither supports nor contradicts the specific mechanism proposed.",
          "key_findings": "Old age and high blood pressure are identified as risk factors for atrial fibrillation and are said to induce structural and electrical atrial remodeling, but no details are provided about arterial stiffness or hemodynamic response changes with aging.",
          "pmid": "36434795",
          "title": "Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review).",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that elastic arteries near the heart are most sensitive to age and blood pressure, identifies stiffness as an index of vascular aging, and describes how stiffness alters hemodynamic loads (pulsatile loads to brain/kidneys, LV systolic load, diastolic pressure for coronary perfusion). This directly aligns with the proposed mechanism that aging increases arterial stiffness, which in turn alters hemodynamic responses to blood pressure changes.",
          "key_findings": "1) Structural arterial stiffness is influenced by blood pressure and age, with elastic arteries being most sensitive to these determinants. 2) Stiffness is considered an index of vascular aging, distinguishing early from supernormal vascular aging. 3) Increased stiffness alters hemodynamics by increasing pulsatile loads in brain and kidney microvasculature and increasing left ventricular systolic load, while excessive pulsatility decreases diastolic pressure needed for coronary perfusion. 4) A feedback loop is described in which stiffness promotes small artery inward remodeling, increasing resistance and blood pressure and further increasing central artery stiffness.",
          "pmid": "33793325",
          "title": "Arterial Stiffness and Cardiovascular Risk in Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses magnesium deficiency, hypertension, and aging, but it does not mention arterial stiffness, vascular compliance, or altered hemodynamic responses as a function of arterial stiffening. Therefore, it neither supports nor contradicts the specific mechanism that age-related increases in arterial stiffness alter hemodynamic responses to blood pressure changes.",
          "key_findings": "The abstract states that: (1) hypertension increases sharply with advancing age; (2) there is extensive evidence for a relationship between magnesium deficit and high blood pressure; (3) older adults are more frequently at risk of magnesium deficiency, which may partly explain their higher hypertension rates and complications; and (4) dietary magnesium and, when needed, supplementation may have a favorable effect on hypertension. No data are presented about arterial stiffness or its role in hemodynamic responses.",
          "pmid": "33396570",
          "title": "Magnesium and Hypertension in Old Age.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiovascular aging in general terms and mentions structural and functional alterations of vessels with age, but it does not specifically address arterial stiffness or how it alters hemodynamic responses to blood pressure changes. Therefore, it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "The review notes that structural and functional vascular changes accumulate with age and increase CVD risk, and it summarizes mechanisms such as endothelial dysfunction, mitochondrial oxidative stress, chromatin remodeling, and genomic instability in cardiovascular aging, but it does not explicitly mention arterial stiffness or consequent hemodynamic response changes.",
          "pmid": "28408026",
          "title": "The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension, frailty, and blood pressure management in older adults but does not mention arterial stiffness, changes in vascular compliance, or specific hemodynamic response alterations with aging. Therefore, it neither supports nor contradicts the proposed mechanism about age-related increases in arterial stiffness altering hemodynamic responses to blood pressure changes.",
          "key_findings": "The abstract states that hypertension is common in older adults, frailty and hypertension often coexist, frailty affects blood pressure management and prognosis, and there is uncertainty about optimal blood pressure targets and antihypertensive regimens in frail elderly patients. No mechanistic discussion of arterial stiffness or hemodynamic response changes is provided.",
          "pmid": "39006023",
          "title": "Hypertension in frail older adults: current perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of music therapy on blood pressure, heart rate, and anxiety in older adults with hypertension, but it does not measure or discuss arterial stiffness, age-related vascular changes, or altered hemodynamic responses. Thus, it neither supports nor contradicts the proposed mechanism about aging-related arterial stiffness and hemodynamics.",
          "key_findings": "In a randomized controlled trial of 60 older adults with hypertension in a nursing home, those receiving music therapy showed significant reductions in systolic blood pressure, heart rate, and anxiety levels compared with a control group.",
          "pmid": "35312440",
          "title": "Music Therapy as an Intervention to Reduce Blood Pressure and Anxiety Levels in Older Adults With Hypertension: A Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses menopause, metabolic syndrome, hypertension, and cardiovascular risk, but does not address age-related arterial stiffness or how stiffness alters hemodynamic responses to blood pressure changes. No measures of arterial stiffness (e.g., pulse wave velocity) or mechanistic discussion of vascular compliance are presented, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Menopause increases the incidence of metabolic syndrome and is associated with central obesity, possible increased insulin resistance, lipid changes largely due to weight gain, and an inconclusive association with hypertension. Metabolic syndrome during menopause appears to raise cardiovascular disease and type 2 diabetes risks. Surgical menopause is strongly linked to higher incidence of metabolic syndrome. None of these findings specifically address arterial stiffness or hemodynamic responses to blood pressure changes with aging.",
          "pmid": "30179134",
          "title": "Metabolic Syndrome During Menopause.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses cardiovascular aging broadly and mentions age-associated alterations in cardiovascular structure and function, but it does not specifically describe increased arterial stiffness or its impact on hemodynamic responses to blood pressure changes.",
          "key_findings": "The article addresses age-related changes in cardiovascular structure and function and highlights the need to characterize these changes (e.g., via the Baltimore Longitudinal Study on Aging), but no concrete findings about arterial stiffness or altered hemodynamic responses are provided in the abstract.",
          "pmid": "10918640",
          "title": "Cardiovascular aging in health.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity-related hypertension through multiple mechanisms (insulin, sympathetic nervous system, renal sodium handling, leptin, cardiac structure, and general hemodynamic alterations), but it does not address age-related changes in arterial stiffness or how aging modifies hemodynamic responses to blood pressure changes. Therefore it neither supports nor contradicts the specific proposed mechanism about aging and arterial stiffness.",
          "key_findings": "Obesity is linked to hypertension via interactions among demographic, genetic, hormonal, renal, and hemodynamic factors; hyperinsulinemia and leptin may increase blood pressure via SNS activation and sodium retention; obesity alters cardiovascular hemodynamics and leads to eccentric myocardial hypertrophy; many of these abnormalities and hypertension can be improved by weight loss. Age is mentioned only as a modifier of the obesity\u2013hypertension association strength, not in relation to arterial stiffness or age-related hemodynamic responses.",
          "pmid": "10505492",
          "title": "Obesity and hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiovascular changes and altered blood pressure control in childhood obesity but does not mention aging, arterial stiffness, or hemodynamic responses specifically related to age-related arterial stiffening. The mechanism concerns age-associated arterial stiffness, whereas the abstract focuses on obesity-related cardiovascular changes in children.",
          "key_findings": "Childhood obesity is linked to early pathological changes in vasculature, heart, and autonomic nervous system that affect blood pressure control and increase later cardiovascular morbidity and mortality, but no details are given about age-related arterial stiffness or its impact on hemodynamic responses.",
          "pmid": "29108535",
          "title": "[Cardiovascular changes in childhood obesity].",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that the increase in blood pressure with age is mostly associated with structural changes in the arteries, especially large artery stiffness, directly linking aging to increased arterial stiffness and altered blood pressure characteristics, which reflects altered hemodynamic responses.",
          "key_findings": "1) Isolated systolic hypertension is the most prevalent hypertension subtype in those aged 50 or over. 2) The increase in blood pressure with age is mostly associated with structural changes in the arteries and especially with large artery stiffness. 3) In the elderly, increased pulse pressure due to decreased diastolic and increased systolic blood pressure is a powerful predictor of cardiovascular risk.",
          "pmid": "17308214",
          "title": "Blood pressure and ageing.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that arterial stiffness increases with age and links this age-related stiffness to altered hemodynamic characteristics (systolic hypertension and wide pulse pressure). This directly supports the proposed mechanism that aging increases arterial stiffness, which alters hemodynamic responses to blood pressure changes.",
          "key_findings": "1) Systolic hypertension in the elderly is associated with a wide pulse pressure resulting largely from excessive large artery stiffness. 2) Arterial stiffness increases with age independently of mean blood pressure or other risk factors. 3) The review discusses effects of age and blood pressure on arterial stiffness and arterial compliance, indicating age-driven changes in vascular properties that affect blood pressure dynamics.",
          "pmid": "11773714",
          "title": "Pathophysiology of hypertension in the elderly.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses causes and clinical syndromes of lacunar infarcts, including various small-vessel arteriopathies and mentions hemodynamic disorders as possible causes, but it does not address aging, arterial stiffness, or how stiffness alters hemodynamic responses to blood pressure changes. Therefore it neither supports nor contradicts the specific aging-related arterial stiffness mechanism.",
          "key_findings": "Lacunar infarcts arise from disease of deep perforating arteries (100\u2013400 \u03bcm), with causes including microatheroma, lipohyalinosis, fibrinoid necrosis, Charcot\u2013Bouchard aneurysm, amyloid angiopathy, CADASIL, and unspecified hemodynamic disorders; diagnosis is by MRI and prognosis is generally good.",
          "pmid": "16833026",
          "title": "Lacunar infarct.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that with advancing age the arterial tree thickens and decreases in compliance (i.e., becomes stiffer), which alters hemodynamics by increasing pulse wave velocity, systolic blood pressure, and left ventricular afterload. This directly aligns with the proposed mechanism that aging increases arterial stiffness and thereby changes hemodynamic responses to blood pressure.",
          "key_findings": "With aging, the arterial tree thickens and decreases in compliance, leading to increased pulse wave velocity, higher systolic blood pressure, and increased left ventricular afterload; the myocardium remodels in response to these arterial changes to maintain function.",
          "pmid": "31845364",
          "title": "Cardiac changes associated with vascular aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how smoking increases vascular risk in hypertensive patients via mechanisms such as increased sympathetic tone, platelet stickiness, free radical production, endothelial damage, and surges in arterial pressure. It does not address age-related changes in arterial stiffness or how aging alters hemodynamic responses to blood pressure changes. Thus, it is related to vascular and blood pressure dynamics but does not provide evidence for or against the specific mechanism of aging-induced arterial stiffness affecting hemodynamic responses.",
          "key_findings": "Smoking increases risk of vascular damage in hypertensive patients by increasing sympathetic tone, platelet reactivity, free radical production, endothelial damage, and causing surges in arterial pressure, which may interfere with some antihypertensive drugs. Risk declines rapidly after smoking cessation.",
          "pmid": "8268884",
          "title": "Smoking and hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly states that in elderly patients arterial stiffness and high aortic systolic pressure are key pathophysiologic features and that vasodilating beta-blockers are preferred in this group for their favorable hemodynamic profile. This acknowledges that age-related arterial stiffness alters hemodynamic responses (e.g., aortic systolic pressure characteristics) and guides drug choice based on these altered responses, aligning with the proposed mechanism. However, it does not present direct experimental or quantitative data on how stiffness changes hemodynamics, so support is inferential rather than strongly mechanistic.",
          "key_findings": "1) The authors distinguish hypertension pathophysiology in young patients (sympathetic hyperactivity) versus elderly patients, in whom \u2018arterial stiffness\u2019 and \u2018high aortic systolic pressure\u2019 predominate. 2) They recommend vasodilating beta-blockers in elderly patients because of a \u2018favourable hemodynamic profile\u2019 in this context. 3) This framing indicates that age-related arterial stiffness in older adults is recognized as altering central hemodynamics (notably aortic systolic pressure), which in turn influences antihypertensive treatment selection.",
          "pmid": "37166681",
          "title": "Beta-Blockers and Hypertension: Some Questions and Answers.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that aging is associated with vascular stiffness and describes how this stiffness alters hemodynamics (wave reflection, systolic blood pressure, pulse pressure, and transmission of pulsatility to microvessels), which aligns directly with the proposed mechanism that arterial stiffness increases with aging and changes hemodynamic responses to blood pressure.",
          "key_findings": "The abstract notes that: (1) Hypertension and aging share mechanisms including vascular stiffness; (2) Large artery stiffening is linked to altered wave reflection from microvascular sites, increasing systolic and pulse pressure; (3) Transmission of increased arterial pulsatility to microvessels is proposed as a mechanism of damage; (4) There is cross-talk between large and small artery changes that interact with pressure wave transmission and reflection, affecting cardiovascular and renal outcomes.",
          "pmid": "31144248",
          "title": "Vascular Aging and Disease of the Small Vessels.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hemodynamic characteristics of obesity-induced hypertension (e.g., high cardiac output, high plasma volume, peripheral resistance) but does not address age-related changes in arterial stiffness or how aging alters hemodynamic responses to blood pressure changes. Therefore, it neither supports nor contradicts the specific mechanism about arterial stiffness increasing with aging.",
          "key_findings": "Obese hypertensive subjects exhibit high cardiac output, high plasma and total blood volume, and inappropriately normal total peripheral resistance; they are more likely to develop left ventricular hypertrophy and kidney damage; neurobiological and hormonal factors such as insulin, leptin, and the adrenergic system are implicated in obesity-induced hypertension. No mention is made of aging-related arterial stiffness or age-dependent hemodynamic responses.",
          "pmid": "11887431",
          "title": "Hypertension in obesity.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that ageing has a marked effect on large arteries and that many studies show a significant relationship between age and aortic stiffness. It also details how stiffness is related to blood pressure (mean/distending pressure) and hypertension, indicating that increased arterial stiffness with age alters hemodynamic responses to blood pressure and antihypertensive treatment. This directly supports the mechanism that arterial stiffness increases with aging and affects hemodynamics.",
          "key_findings": "1) Ageing exerts a marked effect on large arteries, with many cross-sectional studies demonstrating a significant relationship between age and aortic stiffness. 2) Arterial stiffness is closely related to mean arterial (distending) pressure, which confounds stiffness measurements and must be considered when assessing hypertensive subjects or drug effects. 3) Both peripheral and central arteries are stiffer in mixed hypertension compared to normotension, and isolated systolic hypertension is associated with increased aortic stiffness. 4) Antihypertensive agents influence arterial stiffness, primarily via lowering mean pressure, underscoring that age-related stiffness changes have important hemodynamic consequences.",
          "pmid": "17581227",
          "title": "Age, hypertension and arterial function.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses androgens, atherosclerosis, vasodilation, ischemia, and endothelial dysfunction in cardiovascular disease, but it does not address age-related changes in arterial stiffness, nor how such stiffness alters hemodynamic responses to blood pressure changes. There is no mention of arterial stiffness, pulse wave velocity, or age-associated changes in vascular compliance, so the proposed aging\u2013arterial stiffness\u2013hemodynamic response mechanism is neither supported nor contradicted.",
          "key_findings": "The abstract reports: (1) gender differences in age-specific cardiovascular death rates; (2) the role of androgens in early plaque formation and nongenomic vasodilation of vascular smooth muscle; (3) lower blood testosterone levels among men with cardiovascular disease and modest improvement in cardiac ischemia with testosterone therapy; and (4) shared mechanisms such as endothelial dysfunction underlying erectile dysfunction and generalized atherosclerosis. None of these findings specifically address aging-related increases in arterial stiffness or consequent changes in hemodynamic responses to blood pressure.",
          "pmid": "12788802",
          "title": "Androgens and cardiovascular disease.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Older adults experience reduced renal and hepatic function, affecting drug clearance and potentially increasing the drug's half-life, impacting efficacy and adverse effects.",
        "evidence_level": "moderate"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND (age OR elderly OR geriatric) AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"potentially\" OR \"experience\" OR \"increasing\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 3,
      "conflict_count": 2,
      "neutral_count": 15,
      "support_percentage": 15.0,
      "conflict_percentage": 10.0,
      "support_ratio": 0.15,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates efficacy and safety of intermittent intravenous levosimendan in advanced heart failure but does not report on age-related changes in renal or hepatic function, drug clearance, half-life, or how these pharmacokinetic factors in older adults affect efficacy or adverse events.",
          "key_findings": "Intermittent levosimendan infusions reduced NT-proBNP AUC, heart failure hospitalizations, and risk of HRQoL decline compared with placebo, with similar adverse event rates between groups. No measurements or analyses of renal/hepatic function, drug clearance, or age-stratified pharmacokinetics are described.",
          "pmid": "29405611",
          "title": "Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how shift work and long working hours during pregnancy affect maternal and fetal outcomes, without discussing age-related changes in renal or hepatic function, drug clearance, pharmacokinetics, or medication effects in older adults. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Rotating shifts, fixed night shifts, and longer working hours during pregnancy are associated with increased odds of adverse outcomes such as preterm delivery, miscarriage, low birthweight, small for gestational age, preeclampsia, gestational hypertension, and intrauterine growth restriction, but no data on renal/hepatic function or drug half-life in older adults are presented.",
          "pmid": "31276631",
          "title": "The impact of occupational shift work and working\u00a0hours\u00a0during pregnancy on health outcomes:\u00a0a\u00a0systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on magnesium depletion, kidney reabsorption, systemic inflammation, and cardiovascular mortality, but does not address age-related changes in renal or hepatic drug clearance, drug half-life, or pharmacokinetics. No pharmacological agents, dosing, or clearance mechanisms are evaluated, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "A magnesium depletion score (MDS) related to kidney reabsorption was developed and validated. Higher MDS predicted magnesium deficiency better than serum magnesium alone, was associated with higher C-reactive protein, and with increased total and cardiovascular mortality, particularly among individuals with magnesium intake below the Estimated Average Requirement. The study pertains to magnesium status and cardiovascular outcomes, not to drug clearance or age-related renal/hepatic pharmacokinetics.",
          "pmid": "34038556",
          "title": "Magnesium Depletion Score (MDS) Predicts Risk of Systemic Inflammation and Cardiovascular Mortality among US Adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses efficacy, safety, and age-independence of blood pressure response to vasopeptidase inhibitors but provides no data on renal or hepatic function, pharmacokinetics, clearance, or half-life in older adults. It does not address age-related organ function changes or their impact on drug disposition.",
          "key_findings": "Vasopeptidase inhibitors (e.g., omapatrilat) inhibit neutral endopeptidase and ACE, lower blood pressure in various hypertension models, and show benefits in heart failure and ischemic heart disease. In humans, they decrease blood pressure regardless of race or age and have safety profiles similar to ACE inhibitors, with angioedema and cough as concerns. No information is given on renal/hepatic function, drug clearance, or half-life differences in older adults.",
          "pmid": "11705582",
          "title": "Vasopeptidase inhibitors.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that older adults have reduced renal and hepatic function that alters drug clearance and half-life, potentially requiring dose adjustments. The abstract explicitly states that elderly patients may be given full adult doses of bupropion, implying that, in practice, no dose reduction is considered necessary in older adults. This recommendation conflicts with the expectation that age-related clearance reduction would meaningfully impact bupropion\u2019s half-life, efficacy, or adverse effects to the extent that dosing should differ by age. However, the abstract does not present direct pharmacokinetic data stratified by age, so the conflict is based on dosing guidance rather than explicit PK comparisons.",
          "key_findings": "1) Bupropion has an elimination half-life of 11\u201314 hours and is extensively metabolized. 2) The authors state that elderly patients may be given full adult doses of bupropion. 3) No age-specific changes in clearance or half-life are described, and no need for altered dosing in older adults is indicated.",
          "pmid": "6140095",
          "title": "Review of bupropion.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses general challenges in dyslipidemia management, including whether to treat elderly patients, but it does not mention renal or hepatic function, drug clearance, changes in half-life, or age-related pharmacokinetics/pharmacodynamics. Therefore, it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Mentions challenges such as whether to treat children, adolescents, and the elderly with lipid-lowering therapy; emphasizes combining therapies for additive benefit without increased side effects; discusses integration of genetic information into preventive care. No data or comments on age-related renal/hepatic function or drug clearance.",
          "pmid": "12028597",
          "title": "Challenges in dyslipidemia.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that aging is associated with consistent pharmacokinetic changes in clearance and half-life, and specifically notes that renal drug clearance is consistently diminished and hepatic metabolism is variably affected in older adults. This directly supports the proposed mechanism that reduced renal and hepatic function in older adults alters drug clearance and half-life, with implications for efficacy and adverse effects.",
          "key_findings": "1) \"The pharmacokinetic changes most consistently seen with aging occur in the volume of distribution, clearance, and half-life of a drug.\" 2) \"Renal drug clearance is consistently diminished with aging.\" 3) \"Hepatic metabolism is more variably affected, and in contrast to renal clearance, no reliable formula exists to estimate hepatic drug clearance.\" 4) The abstract links these changes to increased drug interactions and adverse drug reactions and recommends reduced starting doses and careful monitoring in the very old.",
          "pmid": "10093763",
          "title": "Cardiovascular pharmacology of aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses CADASIL, its clinical features, imaging findings, and the role of Notch3 mutations and GOM deposition in vascular smooth muscle cells. It does not mention age-related changes in renal or hepatic function, drug clearance, pharmacokinetics, or drug half-life in older adults, nor any pharmacological treatment effects or adverse effects. Therefore, it neither supports nor contradicts the proposed mechanism about altered drug clearance in older adults.",
          "key_findings": "The abstract reports that CADASIL is caused by Notch3 mutations, with accumulation of Notch3 ectodomain as granular osmiophilic material in vascular smooth muscle cells, leading to vascular encephalopathy. It provides clinical diagnostic criteria, age of onset, symptom frequencies, imaging and pathological features, and mutation distribution, but no data on renal or hepatic function, pharmacokinetics, or drug effects in older adults.",
          "pmid": "19069156",
          "title": "[CADASIL].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses clonidine toxicity, variability in clinical response, and the role of neurotransmitters, receptors, endogenous opioids, and sympathetic tone, but it does not mention age-related changes, renal/hepatic function, drug clearance, or half-life. Therefore it neither supports nor contradicts the proposed mechanism about altered pharmacokinetics in older adults.",
          "key_findings": "The clinical response and toxicity of clonidine are said to depend on neurotransmitters, receptors, endogenous opioids, and baseline sympathetic tone; current treatment approaches vary and there is a lack of evidence-based guidance. No data are provided on age, organ function, drug clearance, or pharmacokinetics.",
          "pmid": "12126186",
          "title": "Clonidine toxicity revisited.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes verapamil\u2019s hepatic metabolism, high hepatic extraction, clearance approaching liver blood flow, low oral bioavailability, and effects of hepatic dysfunction or altered hepatic blood flow on its disposition, but it does not specifically examine older adults or age-related declines in renal or hepatic function, nor does it quantify changes in half-life, efficacy, or adverse effects in older adults.",
          "key_findings": "Verapamil is eliminated by hepatic metabolism with inactive metabolites excreted in urine and/or feces; systemic clearance after IV dosing approaches liver blood flow; high hepatic extraction leads to low oral bioavailability (~20%); accumulation occurs with multiple oral dosing and apparent oral clearance decreases; hepatic dysfunction or cardiovascular disorders altering hepatic blood flow may change verapamil disposition; a potentially toxic interaction with digoxin may impair renal excretion of digoxin. No data are provided on age-related changes in renal/hepatic function or pharmacokinetics in older adults.",
          "pmid": "6362951",
          "title": "Clinical pharmacokinetics of verapamil.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ticlopidine\u2019s general pharmacokinetics (absorption, metabolism, accumulation, half-life) and advises against use in severe organ failure but does not examine age-related changes in renal or hepatic function, nor does it compare pharmacokinetics or clearance between older and younger adults. It therefore neither supports nor contradicts the specific mechanism that older adults have reduced renal/hepatic function leading to altered drug clearance and half-life.",
          "key_findings": "Ticlopidine is rapidly absorbed, extensively metabolized, and has a terminal elimination half-life of 20\u201350 hours, with 3- to 4-fold accumulation after 2 weeks of 250 mg twice-daily dosing. Ticlopidine alters the clearance of coadministered drugs (reduces clearance of theophylline and antipyrine; lowers cyclosporine concentrations). Use is discouraged in severe organ failure, but no data are presented on age-related renal or hepatic function or differential pharmacokinetics in older adults.",
          "pmid": "8055680",
          "title": "Clinical pharmacokinetics of ticlopidine.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses prostanoid therapies for pulmonary arterial hypertension, their pharmacodynamic effects, routes of administration, and some pharmacokinetic features (e.g., epoprostenol\u2019s short half-life and delivery issues), but it does not address age-related changes in renal or hepatic function, drug clearance, or half-life in older adults. No comparisons by age or organ function are presented, so the proposed mechanism is neither supported nor contradicted.",
          "key_findings": "Epoprostenol has a short half-life and requires continuous IV infusion; alternative prostacyclin analogs (treprostinil, beraprost, iloprost) have different pharmacokinetic properties and routes (subcutaneous, oral, inhaled). Clinical trials show improvements in symptoms, exercise capacity, hemodynamics, and survival in PAH, but with varying adverse event and tolerability profiles. The abstract does not mention effects of age, renal, or hepatic function on these drugs\u2019 clearance or half-life.",
          "pmid": "14720012",
          "title": "Prostanoids for pulmonary arterial hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly states that aging alters the body's response to medicines in terms of pharmacokinetics and susceptibility to adverse effects, which is consistent with age-related changes in drug handling such as reduced renal and hepatic function affecting clearance, half-life, and adverse outcomes, even though kidney and liver are not named specifically.",
          "key_findings": "The abstract notes that aging processes alter pharmacokinetics, pharmacodynamics, and susceptibility to adverse effects in older adults. It also emphasizes that older adults are particularly vulnerable to adverse drug reactions and that inappropriate prescribing increases the risk of drug interactions and adverse reactions in this population.",
          "pmid": "36354419",
          "title": "Assessing Medicines for Use in the Geriatric Population.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cyclosporine\u2019s effect on blood pressure and shows a dose-related hypertensive effect, but it does not analyze or even mention age-related renal or hepatic function, drug clearance, or half-life, nor does it stratify results by age. Thus it provides no direct evidence for or against the proposed mechanism of altered pharmacokinetics in older adults.",
          "key_findings": "Systematic review of 17 randomized, double-blind, placebo-controlled trials shows cyclosporine significantly increases blood pressure in a dose-related fashion: about +5 mmHg at 1\u20134 mg/kg/day and about +11 mmHg at >10 mg/kg/day. The effect is similar after a single dose and with chronic therapy. There is no discussion of age-related renal/hepatic impairment, pharmacokinetics, or differential effects in older adults.",
          "pmid": "20091657",
          "title": "Effect of cyclosporine on blood pressure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of tree nut intake on blood lipids, apolipoproteins, blood pressure, and inflammation in adults, but does not involve any pharmacologic drug, nor does it assess renal or hepatic function, drug clearance, or half-life. Therefore, it does not provide evidence for or against age-related changes in drug pharmacokinetics.",
          "key_findings": "Tree nut intake (per 28.4 g serving/day) lowered total cholesterol, LDL cholesterol, ApoB, and triglycerides, with stronger lipid-lowering effects at higher nut doses (\u226560 g/day) and in individuals with type 2 diabetes for ApoB. No significant effects were found for blood pressure or C-reactive protein, and no meaningful heterogeneity by nut type was observed.",
          "pmid": "26561616",
          "title": "Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pharmacokinetic variability of ARBs (including half-life, bioavailability, elimination) and notes good tolerability even in elderly patients, but it does not analyze or quantify age-related changes in renal or hepatic function, nor their impact on ARB clearance or half-life. No comparison between older and younger adults or explicit linkage of organ function decline to altered PK, efficacy, or adverse effects is provided.",
          "key_findings": "The abstract states that ARBs show differences in lipid solubility, absorption/distribution, plasma protein binding, bioavailability, biotransformation, plasma half-life, and systemic elimination, which influence onset, duration, and efficacy. It also reports a low incidence of adverse effects, including in elderly patients. However, it does not address reduced renal or hepatic function in older adults or its pharmacokinetic consequences.",
          "pmid": "10854085",
          "title": "Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism assumes older adults have reduced renal/hepatic function that alters drug clearance and half-life, impacting efficacy and adverse effects. The abstract explicitly states that terazosin pharmacokinetics are not significantly affected by age or renal impairment, and that adverse events are usually not age related, directly contradicting the expectation that age-related renal/hepatic decline meaningfully changes terazosin clearance or clinical effects.",
          "key_findings": "The abstract reports: (1) terazosin has a half-life of about 12 hours and shows linear pharmacokinetics; (2) its pharmacokinetics are not significantly affected by food, age, hypertension, or renal impairment; (3) adverse events are usually minor and not age related. These findings indicate that age-related changes in renal function do not materially alter terazosin pharmacokinetics or adverse event incidence in this dataset.",
          "pmid": "1678920",
          "title": "Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thiazide diuretics\u2019 efficacy, side effects, and impact on cardiovascular risk factors in both young and elderly subjects, but it does not address age-related changes in renal or hepatic function, drug clearance, or altered half-life. No pharmacokinetic data or age-specific clearance effects are described, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Thiazide diuretics are effective in reducing blood pressure with minimal subjective side effects; they may cause changes in plasma lipid profile, serum uric acid, and glucose metabolism, which are generally not clinically significant. Diuretics reduce morbidity and mortality in essential hypertension in both young and elderly subjects, with low incidence of diabetes and rare gout. No information is provided on renal/hepatic function, drug clearance, or half-life differences in older adults.",
          "pmid": "1486910",
          "title": "Diuretics and cardiovascular risk factors.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study evaluates safety and pharmacokinetics of inhaled treprostinil palmitil in healthy adults aged 18\u201345, reporting half-life, exposure, and tolerability. It does not examine older adults, age-related changes in renal or hepatic function, or how such changes impact drug clearance, half-life, efficacy, or adverse effects. Therefore it neither supports nor contradicts the proposed age-related clearance mechanism.",
          "key_findings": "In healthy volunteers (18\u201345 years), treprostinil after TPIP showed an elimination half-life of ~6.8\u201311.6 hours, dose-proportional exposure, no steady-state accumulation, and mostly mild adverse events. Plasma concentrations of the prodrug (treprostinil palmitil) were below the limit of quantification. No data on older adults or on renal/hepatic impairment were reported.",
          "pmid": "36070132",
          "title": "Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase\u00a01, Randomized, Double-Blind, Single- and Multiple-Dose Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly states that advanced age leads to a progressive decline in resting organ function, with specific mention of diminished renal capacity and altered pharmacokinetics and pharmacodynamics, which in turn increase untoward reactions to medications. This is consistent with the proposed mechanism that older adults have reduced renal (and more generally organ) function affecting drug clearance and thereby influencing efficacy and adverse effects. While hepatic function is not explicitly mentioned, the discussion of impaired organ function and drug metabolism in general supports the mechanistic concept.",
          "key_findings": "1) Advanced age is accompanied by a progressive decline in resting organ function and reduced reserve capacity to compensate for impaired organ function and drug metabolism. 2) Age-related decline in organ function includes diminished renal capacity to conserve and eliminate water and salt. 3) With advancing age, altered pharmacokinetics and pharmacodynamics and increased intake of medications lead to a higher incidence of untoward reactions to medications, anaesthetic agents, and interventions.",
          "pmid": "11094595",
          "title": "The aged cardiovascular risk patient.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "The absolute benefit of blood pressure reduction may be higher in older adults due to their higher baseline risk.",
        "evidence_level": "moderate"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND (age OR elderly OR geriatric) AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"reduction\" OR \"baseline\" OR \"pressure\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The mechanism concerns whether the absolute benefit of blood pressure reduction is greater in older adults because of their higher baseline risk. The abstract focuses only on older adults and compares more vs less aggressive BP targets within this population, showing that lower targets reduce stroke and serious cardiovascular events but have unclear impact on mortality. It does not compare the magnitude of absolute benefit between older and younger adults, nor does it quantify how baseline risk modifies absolute benefit within age strata. Therefore it neither directly supports nor contradicts the proposed age-related increase in absolute benefit.",
          "key_findings": "In adults \u226565 years, lower BP targets (<140/90 mmHg or 110\u2013130 mmHg systolic) versus higher targets (130\u2013150 or <150\u2013160/95\u2013105 mmHg) over 2\u20134 years: (1) probably reduce total serious cardiovascular adverse events (RR 1.25, 95% CI 1.09\u20131.45; moderate-certainty evidence) and reduce stroke (RR 1.33, 95% CI 1.06\u20131.67; high-certainty evidence); (2) show little to no difference in all-cause mortality (RR 1.14, 95% CI 0.95\u20131.37; low-certainty evidence); and (3) likely do not increase withdrawals due to adverse effects (RR 0.99, 95% CI 0.74\u20131.33; moderate-certainty evidence). No comparison is made to younger populations or to absolute risk differences across age groups.",
          "pmid": "39688187",
          "title": "Higher blood pressure targets for hypertension in older adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes age-related physiological changes including higher blood pressures in older adults, but it does not discuss treatment, blood pressure reduction, or comparative absolute benefit of such reduction. It therefore neither supports nor refutes the claim that older adults derive greater absolute benefit from blood pressure lowering due to higher baseline risk.",
          "key_findings": "With aging, the cardiovascular system develops higher blood pressures with lower cardiac output, and multiple organ systems undergo physiologic decline, creating a complex condition that must be considered for geriatric patients undergoing general anesthesia.",
          "pmid": "26315630",
          "title": "Physiology Considerations in Geriatric Patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses that hypertension and its risks are more prevalent and multidimensional in older adults, but it does not address the absolute benefit of blood pressure reduction, treatment effects by age, or whether benefit is greater in older adults due to higher baseline risk. It focuses on risks and mechanisms, not on treatment benefit magnitudes.",
          "key_findings": "Hypertension is most incident among older adults; it carries cardiovascular and collateral risks such as dementia, disability, and falls/fractures; shared mechanisms include inflammation, oxidative stress, and endothelial dysfunction; the review aims to discuss risks, treatment strategies, and research directions in older adults with hypertension.",
          "pmid": "26835847",
          "title": "Hypertension and aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension prevalence, its role in cardiovascular morbidity and mortality, and general treatment strategies, but it does not compare absolute benefits of blood pressure reduction by age or baseline risk, nor does it quantify treatment benefit across age groups.",
          "key_findings": "Hypertension is common and a leading cause of cardiovascular morbidity and mortality; guidelines focus on total cardiovascular risk, rational antihypertensive combinations, and lifestyle interventions. No age-stratified data or discussion of absolute benefit differences in older versus younger adults is provided.",
          "pmid": "18092636",
          "title": "Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "low",
          "reasoning": "The provided abstract text is only the title and contains no results or discussion about blood pressure reduction, treatment effects, or comparative absolute benefit in older versus younger adults. It focuses on arterial and cardiac aging as contributors to cardiovascular disease risk, but does not address intervention benefits or baseline-risk\u2013dependent absolute benefit.",
          "key_findings": "From the title alone, the article concerns aging arteries and their role in vascular disease, implying increased cardiovascular risk with aging, but offers no data or statements about the magnitude of benefit from blood pressure lowering in older adults.",
          "pmid": "12515756",
          "title": "Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a \"set up\" for vascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex- and hormone-related differences in autonomic control of blood pressure and cerebral blood flow, including age- and sex-hormone-related differences, but does not address treatment, blood pressure reduction interventions, baseline cardiovascular risk, or absolute benefit of lowering blood pressure in older adults. Therefore it neither supports nor contradicts the proposed mechanism about greater absolute benefit of BP reduction in older adults due to higher baseline risk.",
          "key_findings": "The review highlights sex- and sex-hormone-specific differences in autonomic blood pressure control, central haemodynamics, and cerebral blood flow, including age- and hormone-related differences, and suggests potential clinical implications, but does not evaluate outcomes or benefits of blood pressure reduction by age.",
          "pmid": "28799254",
          "title": "Sex-specific factors regulating pressure and flow.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that recent studies support lower, more aggressive blood pressure targets in older patients, but it does not quantify absolute benefit, compare benefit by age group, or relate outcomes to baseline risk. Therefore it does not address whether the absolute benefit of BP reduction is higher in older adults due to higher baseline risk.",
          "key_findings": "Recent studies have supported lower, more aggressive blood pressure targets in the management of hypertension, even in older patients, though controversy remains regarding cognitive and functional effects.",
          "pmid": "27313081",
          "title": "Geriatrics: Year in review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aging as a risk factor for developing hypertension and describes age-associated blood pressure elevation and phenotypes in elderly hypertension, but it does not address treatment effects, risk reduction, or compare the absolute benefit of blood pressure lowering between older and younger adults. Therefore, it neither supports nor contradicts the claim that absolute benefit of BP reduction is higher in older adults due to higher baseline risk.",
          "key_findings": "Aging is a dominant risk factor in progression of hypertension; age-associated BP elevation results from aging of organ systems regulating BP; advanced cardiovascular aging leads to varied hypertension phenotypes (e.g., nocturnal and morning hypertension); managing hypertension in the elderly is an urgent task; 24-hour ambulatory BP monitoring is important for detecting and treating age-associated hypertension.",
          "pmid": "21090928",
          "title": "Aging and hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract states that treating elderly hypertensive patients reduces cardiovascular events and that elderly individuals have high cardiovascular risk from elevated blood pressure, but it does not quantify or compare the absolute benefit of blood pressure reduction between older and younger adults. Thus, it does not directly address whether the absolute benefit is higher in older adults due to higher baseline risk.",
          "key_findings": "1) Rising blood pressure is associated with increased cardiovascular risk, and in the elderly, increased pulse pressure is a powerful predictor of risk. 2) All evidence indicates that treating elderly hypertensive patients reduces the risk of cardiovascular events. 3) There is no evidence yet for the very elderly, who are more susceptible to treatment side effects and in whom blood pressure reduction may reduce stroke but potentially increase mortality.",
          "pmid": "17308214",
          "title": "Blood pressure and ageing.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the pathophysiology of hypertension and arterial stiffness in the elderly but does not address treatment effects, absolute benefit of blood pressure reduction, or how benefit varies with baseline cardiovascular risk or age. Therefore it neither supports nor contradicts the proposed mechanism about greater absolute benefit in older adults.",
          "key_findings": "Systolic hypertension is common in the elderly and is a major modifiable cardiovascular risk factor; it is associated with wide pulse pressure largely due to increased large artery stiffness. Arterial stiffness increases with age independently of mean blood pressure or other risk factors. The role of age and gender in arterial stiffness and wave reflection, especially in those over 70, remains poorly investigated and requires further research.",
          "pmid": "11773714",
          "title": "Pathophysiology of hypertension in the elderly.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex hormones, gender, and menopausal status in relation to blood pressure levels, but it does not address how the absolute *benefit* of blood pressure reduction differs by age or baseline risk. There is no evidence about treatment effects, risk reduction, or age-related differences in benefit magnitude, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Premenopausal women have lower arterial blood pressure than age-matched men, and postmenopausal women have higher blood pressure than premenopausal women, suggesting ovarian hormones may modulate blood pressure. The review covers potential blood pressure\u2013regulating effects and mechanisms of sex hormones but does not evaluate the absolute benefit of blood pressure reduction in older versus younger adults.",
          "pmid": "11861040",
          "title": "Sex hormones and hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aging as a major risk factor for hypertension and cardiovascular disease and reviews the role of the renin-angiotensin system and autonomic control in aging. However, it does not address the absolute benefit of blood pressure reduction, nor compare treatment effects or risk reductions by age group, so it provides no direct evidence about whether absolute benefit of BP lowering is greater in older adults.",
          "key_findings": "Aging is described as the greatest independent risk factor for hypertension and various cardiovascular diseases, with associated autonomic imbalance and involvement of the renin-angiotensin system. The paper is a review of mechanisms and pharmacological strategies targeting RAS in aging, but it does not quantify treatment benefit, absolute risk reduction, or age-specific effects of blood pressure lowering.",
          "pmid": "34973286",
          "title": "The renin-angiotensin system and cardiovascular autonomic control in aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses mechanisms of age-related hypertension and a potential treatment (thioredoxin) but does not address the comparative *absolute benefit* of blood pressure reduction in older versus younger adults, nor does it analyze how baseline cardiovascular risk modifies treatment benefit.",
          "key_findings": "Age-related hypertension is common and contributes to cardiovascular disease; thioredoxin overexpression or recombinant thioredoxin administration in aged mice reverses hypertension, increases nitric oxide production, decreases arterial stiffness, and improves vascular relaxation. The abstract recommends intensive blood pressure management in patients with cardiovascular complications but does not quantify or compare absolute treatment benefits by age or baseline risk.",
          "pmid": "29445879",
          "title": "Role of Thioredoxin in Age-Related Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract states that blood pressure reduction in the elderly is effective and reduces cardiovascular morbidity and mortality, but it does not quantify absolute benefit, compare it to younger populations, or relate benefit to baseline risk. Therefore it does not directly address whether the absolute benefit is higher in older adults because of higher baseline risk.",
          "key_findings": "Treatment of hypertension in the elderly is described as accepted and highly effective; intervention studies using diuretics and beta-blockers have shown benefits in reducing cardiovascular morbidity and mortality; newer therapies like calcium antagonists may offer further advantages. No comparison by age or baseline risk is provided.",
          "pmid": "9120661",
          "title": "Hypertension in the elderly.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses gut microbiota, its metabolites, and receptor-mediated effects on blood pressure and cardiovascular complications, but it does not compare blood-pressure\u2013lowering benefits across age groups, baseline risk levels, or absolute risk reduction. Therefore it neither supports nor contradicts the claim that older adults experience greater absolute benefit from blood pressure reduction due to higher baseline risk.",
          "key_findings": "Gut microbiota composition and metabolites (e.g., short-chain fatty acids, TMAO) influence hypertension and its complications; specific receptors (GPR41, GPR43, GPR109A, OLF78) affect blood pressure regulation and cardiac function; prebiotics, probiotics, and postbiotics lower blood pressure in animal models. No data or statements address age-stratified benefits or absolute risk reduction related to blood pressure lowering.",
          "pmid": "33012206",
          "title": "Microbial Peer Pressure: The Role of the Gut Microbiota in Hypertension and Its Complications.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between exercise-induced blood pressure responses (hypertensive response to exercise) and cardiac structural remodeling/risk, but it does not compare absolute treatment benefits or risk reduction across age groups, nor does it address baseline cardiovascular risk as a modifier of treatment effect. Therefore it does not provide evidence for or against the claim that the absolute benefit of blood pressure reduction is higher in older adults due to their higher baseline risk.",
          "key_findings": "Exercise systolic blood pressure was positively associated with left ventricular mass and wall thickness measures; individuals with a hypertensive response to exercise had higher risk of LV hypertrophy (RR 2.6 [1.85\u20133.70]) and greater LV mass and related structural indices than those without such a response, with results broadly similar across different study populations.",
          "pmid": "33707155",
          "title": "Exercise blood pressure and cardiac structure: A systematic review and meta-analysis of cross-sectional studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews pharmacology, pharmacokinetics, indications, and side effects of calcium-channel blockers, including some notes about geriatric pharmacokinetics, but it does not compare absolute benefits of blood pressure reduction by age or baseline cardiovascular risk, nor does it quantify treatment effects in older versus younger adults.",
          "key_findings": "Diltiazem shows delayed absorption and reduced clearance in geriatric patients; calcium-channel blockers affect blood pressure regulation and are useful in hypertension and other cardiovascular conditions. However, no data are provided on baseline risk, absolute risk reduction, or age-stratified treatment benefits.",
          "pmid": "6764159",
          "title": "Calcium-channel blocking agents.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiovascular changes and blood pressure control in childhood obesity and the impact of small weight loss on cardiovascular risk, but it does not compare age groups, baseline risk by age, or the absolute benefit of blood pressure reduction in older versus younger adults. Therefore it does not address whether absolute benefit of BP lowering is higher in older adults due to higher baseline risk.",
          "key_findings": "Childhood obesity has increased globally; it is associated with increased adult cardiovascular morbidity and mortality. Pathologic changes in vasculature, heart, and autonomic nervous system affecting blood pressure control are observed even from age two. Early prevention, detection, and treatment of overweight/obesity are recommended, and even small weight loss reduces cardiovascular disease risk.",
          "pmid": "29108535",
          "title": "[Cardiovascular changes in childhood obesity].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension, cardiovascular disease, and COVID-19 severity, as well as hypotheses about ACE inhibitors/ARBs, but does not address age-related differences in the absolute benefit of blood pressure reduction or baseline risk in older adults. There is no analysis of treatment benefit magnitude by age or baseline risk, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Hypertension, diabetes, and cardio/cerebrovascular disease are associated with severe and fatal COVID-19; myocardial damage and dysfunction are suggested as a causal link; elevated troponin and ECG anomalies are frequently observed; there are unproven hypotheses about potential deleterious effects of ACE inhibitors and ARBs; no solid evidence yet and need for properly designed studies. No mention of age-stratified benefits of blood pressure reduction.",
          "pmid": "32591283",
          "title": "[COVID-19 and its relationship with hypertension and cardiovascular disease].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract only provides a title about pulsatile blood flow and no substantive content about age, blood pressure reduction, baseline cardiovascular risk, or absolute treatment benefit, so it does not address the proposed mechanism.",
          "key_findings": "No relevant findings are provided beyond the title; there is no information on blood pressure lowering outcomes in older versus younger adults or differences in absolute risk reduction by age.",
          "pmid": "4555147",
          "title": "Pulsatile blood flow.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "egfr",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "CKD increases cardiovascular risk and alters blood pressure response due to vascular and structural changes.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"egfr\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"cardiovascular\" OR \"structural\" OR \"increases\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 10.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that CKD in patients with type 2 diabetes is associated with high cardiovascular risk and that semaglutide reduces kidney and cardiovascular events. However, it does not investigate or describe how CKD alters blood pressure response or detail vascular and structural changes as the mechanistic basis for increased cardiovascular risk. The focus is on clinical outcomes and treatment effect, not on the specific biological mechanism proposed.",
          "key_findings": "Patients with type 2 diabetes and CKD had high risks of kidney failure, cardiovascular events, and death. Semaglutide versus placebo reduced major kidney disease events (HR 0.76), kidney-specific outcomes (HR 0.79), death from cardiovascular causes (HR 0.71), major cardiovascular events (HR 0.82), all-cause mortality (HR 0.80), and slowed eGFR decline. The abstract does not report blood pressure response characteristics or direct measures of vascular or structural vascular changes.",
          "pmid": "38785209",
          "title": "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates long-term cardiorenal outcomes of empagliflozin in CKD patients but does not examine how CKD itself alters cardiovascular risk or blood pressure response via vascular or structural changes. It reports outcome reductions (kidney disease progression, cardiovascular death) with a drug intervention, without mechanistic assessment of CKD-driven vascular/structural alterations or BP responses.",
          "key_findings": "In CKD patients, empagliflozin vs placebo reduced the composite outcome of kidney disease progression or cardiovascular death (HR 0.79, 95% CI 0.72\u20130.87) over combined active and post-trial follow-up. Cardiovascular death risk was 3.8% vs 4.9% and kidney disease progression 23.5% vs 27.1% for empagliflozin vs placebo. No difference in noncardiovascular death was observed. These findings relate to treatment effects, not the intrinsic mechanistic impact of CKD on cardiovascular risk or blood pressure response.",
          "pmid": "39453837",
          "title": "Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on dialysis indications, modalities, complications, and survival in chronic kidney failure but does not analyze how CKD per se alters cardiovascular risk or blood pressure response through vascular or structural changes. Hypertension and cardiovascular events are mentioned as common complications, yet no mechanistic or comparative data on vascular/structural alterations or blood pressure responses are provided.",
          "key_findings": "1) Chronic kidney failure patients on maintenance dialysis have a 5-year survival of about 40%. 2) Cardiovascular complications such as arrhythmias and cardiac arrest are common in maintenance dialysis. 3) Systemic complications of chronic kidney failure include anemia, hyperphosphatemia, hypocalcemia, and hypertension, often requiring pharmacologic treatment. 4) Hypotension during dialysis is a frequent issue that can interfere with treatment delivery. These findings note cardiovascular and blood pressure-related problems but do not explicitly link them to specific vascular or structural changes as a causal mechanism.",
          "pmid": "39356511",
          "title": "Dialysis for Chronic Kidney Failure: A Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of finerenone on cardiovascular outcomes in patients with CKD and type 2 diabetes, but it does not investigate how CKD itself alters cardiovascular risk or blood pressure response via vascular or structural changes, nor does it measure or analyze blood pressure or specific vascular/structural mechanisms. The improved cardiovascular outcomes with finerenone do not directly address the proposed mechanism about CKD-induced vascular/structural alterations and BP response.",
          "key_findings": "In patients with type 2 diabetes and CKD (various stages with albuminuria), finerenone reduced the composite cardiovascular outcome (HR 0.87; 95% CI 0.76\u20130.98), mainly via reduced hospitalization for heart failure (HR 0.71; 95% CI 0.56\u20130.90). Kidney composite outcome was numerically but not significantly improved (HR 0.87; 95% CI 0.76\u20131.01). Adverse event rates were similar except for a higher rate of hyperkalemia-related discontinuation with finerenone. The study does not analyze or report mechanistic changes in vascular structure, function, or blood pressure response attributable to CKD itself.",
          "pmid": "34449181",
          "title": "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract states that CKD is highly prevalent in acute decompensated heart failure and is one of the strongest risk factors for mortality and cardiovascular events, supporting the idea that CKD increases cardiovascular risk. It also describes hemodynamic and neurohormonal alterations (venous congestion, arterial underfilling, RAAS and sympathetic activation, endothelial dysfunction) that affect vascular tone, sodium handling, and hence blood pressure and perfusion, aligning with the proposed concept that CKD-related cardiorenal interactions alter vascular/structural determinants of blood pressure. However, the discussion of mechanisms is general to cardiorenal syndrome and not exclusive to CKD, so the support is indirect rather than definitive.",
          "key_findings": "1) Upward of 60% of patients admitted for acute decompensated heart failure have CKD (eGFR <60 ml/min/1.73 m\u00b2). 2) CKD is described as one of the strongest risk factors for mortality and cardiovascular events in acute decompensated heart failure. 3) Mechanisms in cardiorenal syndrome include venous congestion, arterial underfilling, neurohormonal activation, inflammation, and endothelial dysfunction, with arterial underfilling leading to RAAS and sympathetic activation, sodium reabsorption, and vasoconstriction, all of which modify vascular function and blood pressure regulation.",
          "pmid": "36787124",
          "title": "Cardiorenal Syndrome in the Hospital.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates dapagliflozin\u2019s effects on kidney and cardiovascular outcomes in patients with CKD, but does not investigate or describe how CKD itself alters cardiovascular risk or blood pressure through vascular or structural changes. It reports outcome reductions with a drug across CKD subgroups, not mechanistic data on CKD-driven cardiovascular risk or BP responses.",
          "key_findings": "Dapagliflozin reduced the risk of a composite kidney and cardiovascular outcome, kidney-specific outcomes, cardiovascular death or heart failure hospitalization, and all-cause mortality in CKD patients, with similar benefit in those with and without type 2 diabetes and across different CKD etiologies. Safety profiles were similar regardless of diabetes status.",
          "pmid": "33338413",
          "title": "Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of dapagliflozin on renal and cardiovascular outcomes in stage 4 CKD but does not investigate or describe how CKD itself increases cardiovascular risk or alters blood pressure response via vascular or structural changes. It reports clinical outcome effects of a drug, not the underlying pathophysiologic mechanism linking CKD to cardiovascular risk or BP changes.",
          "key_findings": "In stage 4 CKD patients, dapagliflozin reduced the primary composite endpoint (\u226550% sustained eGFR decline, ESKD, or kidney/cardiovascular death) by 27% versus placebo and slowed eGFR decline (2.15 vs 3.38 ml/min/1.73 m\u00b2 per year, P=0.005), with similar adverse event rates. These results were consistent with the overall DAPA-CKD trial. The abstract does not report on blood pressure responses, vascular remodeling, or structural cardiovascular changes attributable to CKD itself.",
          "pmid": "34272327",
          "title": "Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism asserts that CKD increases cardiovascular risk; the abstract directly shows that reduced eGFR and increased albuminuria\u2014key markers and definers of CKD\u2014are independently and jointly associated with higher all-cause and cardiovascular mortality in general population cohorts. While the study does not detail vascular or structural pathophysiology or blood pressure responses, it clearly links CKD severity (via eGFR and albuminuria) to increased cardiovascular mortality, supporting the cardiovascular risk component of the mechanism.",
          "key_findings": "1) In >1.2 million participants, lower eGFR below 60 mL/min/1.73 m\u00b2 was progressively associated with higher all-cause and cardiovascular mortality; eGFR 60, 45, and 15 mL/min/1.73 m\u00b2 had adjusted HRs for all-cause mortality of 1.18, 1.57, and 3.14 versus 95 mL/min/1.73 m\u00b2. 2) Higher albumin-to-creatinine ratio (ACR) showed a graded, approximately log-linear increase in all-cause mortality risk, with HRs 1.20, 1.63, and 2.22 for ACR 1.1, 3.4, and 33.9 mg/mmol compared with 0.6 mg/mmol. 3) Similar graded associations were observed for cardiovascular mortality. 4) eGFR <60 mL/min/1.73 m\u00b2 and ACR \u22651.1 mg/mmol were identified as independent predictors of mortality risk, and the combination of reduced eGFR and higher ACR had multiplicative effects on risk.",
          "pmid": "20483451",
          "title": "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes the design and baseline characteristics of a CKD trial (DAPA-CKD), including cardiovascular outcomes as endpoints, but it does not report results on cardiovascular risk, blood pressure responses, or underlying vascular/structural mechanisms. No mechanistic data or outcome associations are presented that would directly support or contradict the claim that CKD increases cardiovascular risk and alters blood pressure response due to vascular and structural changes.",
          "key_findings": "The DAPA-CKD trial enrolled 4304 participants with CKD (eGFR 25\u201375 mL/min/1.73 m2 and UACR \u2265200 mg/g), with and without type 2 diabetes, to test the effect of dapagliflozin on kidney and cardiovascular events. Baseline characteristics (eGFR, UACR, CKD etiologies, and background use of RAAS blockers and other medications) are reported, and comparisons are made with other CKD trials, but no data on cardiovascular risk mechanisms, vascular changes, or blood pressure responses are provided.",
          "pmid": "32862232",
          "title": "The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines acute eGFR changes after starting dapagliflozin in CKD and their association with long-term kidney outcomes and safety, but it does not assess cardiovascular risk, blood pressure responses, or underlying vascular/structural changes. Therefore, it neither supports nor contradicts the proposed mechanism about CKD-driven cardiovascular risk and altered blood pressure response.",
          "key_findings": "In CKD patients with albuminuria in DAPA-CKD, dapagliflozin frequently caused an acute >10% eGFR reduction at 2 weeks, but this early decline was associated with a slower long-term eGFR loss compared with smaller or no acute eGFR reduction. In the placebo group, long-term eGFR decline was similar across acute eGFR-change categories. Acute eGFR changes with dapagliflozin were not associated with higher rates of CKD progression or higher rates of serious or prespecified adverse events.",
          "pmid": "35977807",
          "title": "Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of empagliflozin on kidney disease progression and cardiovascular death across different primary kidney diseases, but it does not analyze how chronic kidney disease per se alters cardiovascular risk or blood pressure responses via vascular or structural changes. It reports clinical outcome effects of a drug, not mechanistic data on CKD-driven vascular remodeling, hemodynamics, or blood pressure regulation.",
          "key_findings": "Empagliflozin reduced the risk of kidney disease progression or cardiovascular death in CKD patients (HR 0.71, 95% CI 0.62\u20130.81) and slowed chronic eGFR decline by about 50%, with similar relative benefits across primary kidney disease categories (diabetic, glomerular, hypertensive/renovascular, other/unknown). The trial does not report mechanistic data on CKD-induced vascular or structural changes, blood pressure responses, or their role in cardiovascular risk.",
          "pmid": "38061372",
          "title": "Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of continuing vs discontinuing renin-angiotensin system inhibitors on kidney outcomes, cardiovascular events, and blood pressure in advanced CKD, but does not investigate or describe how CKD itself increases cardiovascular risk or alters blood pressure responses via vascular or structural changes. It reports clinical outcome data, not mechanistic evidence about CKD-induced vascular/structural alterations.",
          "key_findings": "In patients with advanced CKD (eGFR <30 ml/min/1.73 m\u00b2), discontinuation of RAS inhibitors did not significantly change the long-term rate of eGFR decline compared with continuation; ESKD or renal replacement therapy occurred in 62% vs 56% (HR 1.28, 95% CI 0.99\u20131.65); cardiovascular events (108 vs 88) and deaths (20 vs 22) were similar between groups; no heterogeneity across prespecified subgroups. These findings concern treatment effects and outcomes, not the mechanism that CKD per se alters cardiovascular risk and blood pressure through vascular/structural changes.",
          "pmid": "36326117",
          "title": "Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial evaluates cardiovascular and renal outcomes in patients with type 2 diabetes and high CV/renal risk treated with linagliptin vs placebo, but it does not analyze how chronic kidney disease mechanistically alters cardiovascular risk or blood pressure responses, nor does it assess vascular or structural changes as mediators. Outcomes are event-based (CV death, MI, stroke, renal failure/ESRD/eGFR decline) without mechanistic measurements related to vascular structure or BP response.",
          "key_findings": "In high cardiovascular and renal risk type 2 diabetes patients (mean eGFR 54.6 mL/min/1.73 m\u00b2, 80.1% with albuminuria), linagliptin was noninferior to placebo regarding composite major cardiovascular events (HR 1.02, 95% CI 0.89-1.17) and showed similar kidney outcomes (HR 1.04, 95% CI 0.89-1.22). The study does not report effects of CKD per se on cardiovascular risk, blood pressure response, or vascular/structural changes; CKD is part of the inclusion criteria but not the mechanistic focus.",
          "pmid": "30418475",
          "title": "Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract investigates genetic loci associated with longitudinal eGFR decline in CKD patients. It does not assess cardiovascular risk, blood pressure responses, or vascular/structural changes as mediators of these outcomes. Therefore, it neither supports nor contradicts the proposed mechanism that CKD increases cardiovascular risk and alters blood pressure response via vascular and structural changes.",
          "key_findings": "Three loci (UMOD/PDILT, BICC1, HEATR4/APOL1 region) were associated with differences in longitudinal eGFR decline among CKD patients, with effect sizes quantified as percent per year change in eGFR slope. Associations varied by ethnicity and diabetes status, and some loci with prior links to eGFR decline (PRKAG2, FGF5, C15ORF54) were nominally replicated. The study focuses on genetic determinants of kidney function decline, not on cardiovascular risk or blood pressure mechanisms.",
          "pmid": "37261792",
          "title": "Genome-Wide Association Study of CKD Progression.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates renal function (eGFR, albuminuria) and cardiovascular outcomes in heart failure patients treated with sacubitril/valsartan versus enalapril, including those with CKD. It does not investigate how CKD per se alters blood pressure responses or cardiovascular risk through vascular or structural changes, nor does it discuss mechanisms of CKD-driven hemodynamic or vascular remodeling. Thus it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "In PARADIGM-HF, 33% of patients had CKD at baseline. Sacubitril/valsartan produced a slower decline in eGFR than enalapril despite a greater increase in UACR. The beneficial effect of sacubitril/valsartan on cardiovascular death or heart failure hospitalization was consistent regardless of baseline eGFR, UACR, or change in UACR. The study does not address CKD-induced vascular/structural changes or altered blood pressure responses as mechanistic drivers of cardiovascular risk.",
          "pmid": "29655829",
          "title": "Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the effects of incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) on diabetic microvascular complications, especially nephropathy and other microvascular outcomes. It does not examine how chronic kidney disease per se alters cardiovascular risk or blood pressure response via vascular or structural changes. CKD is mentioned only indirectly through nephropathy/renal outcomes, without analysis of cardiovascular risk modulation or blood pressure responses in CKD.",
          "key_findings": "GLP-1 receptor agonists reduce composite renal outcomes in clinical trials; DPP-4 inhibitors reduce albuminuria and may reduce peripheral neuropathy risk; the relationship of these agents with retinopathy is mixed, with some increased risk signals (e.g., semaglutide, DPP-4 inhibitors) in certain contexts. Evidence for other microvascular outcomes (microvascular angina, cerebral small vessel disease, autonomic neuropathies) is sparse. No data are presented on how CKD modifies cardiovascular risk or blood pressure responses through vascular or structural changes.",
          "pmid": "37597048",
          "title": "Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of sotagliflozin on major adverse cardiovascular events in patients with type 2 diabetes and chronic kidney disease, but it does not investigate how CKD itself alters cardiovascular risk or blood pressure response via vascular or structural changes. The observed reductions in MACE, myocardial infarction, and stroke with drug treatment do not specifically address CKD-driven vascular/structural mechanisms or blood pressure responses.",
          "key_findings": "In the SCORED trial, patients with type 2 diabetes and CKD treated with sotagliflozin had lower rates of total major adverse cardiovascular events (HR 0.77, 95% CI 0.65\u20130.91), myocardial infarction (HR 0.68, 95% CI 0.52\u20130.89), and stroke (HR 0.66, 95% CI 0.48\u20130.91) compared with placebo, with consistent effects across prespecified subgroups. The study did not analyze CKD-related vascular or structural changes or blood pressure response as mechanistic mediators.",
          "pmid": "39961315",
          "title": "Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses long-term renal outcomes (kidney damage, eGFR), urinary tract infections, and some incidence of hypertension in children with antenatally detected urinary tract dilatation. It does not analyze chronic kidney disease as a condition that alters cardiovascular risk or blood pressure response via vascular or structural changes, nor does it examine mechanisms of CKD-related vascular remodeling or hemodynamics. The mention of uncommon hypertension is descriptive, not mechanistic, and not clearly framed as CKD-driven cardiovascular alteration.",
          "key_findings": "Among children with moderate or severe antenatal urinary tract dilatation, permanent kidney damage is seen in ~40%, but hypertension, proteinuria, and reduced eGFR are uncommon (0\u20135%); children with mild dilatation generally have excellent long-term outcomes. The review does not evaluate how CKD influences cardiovascular risk or blood pressure responses via vascular or structural changes.",
          "pmid": "36920569",
          "title": "Antenatally detected urinary tract dilatation: long-term outcome.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the causal effect of obesity (BMI/WHR) and type 2 diabetes on kidney function using Mendelian randomization, and also tests whether genetically predicted kidney function affects obesity. It does not study how CKD changes blood pressure responses or cardiovascular risk via vascular/structural changes, nor does it evaluate hemodynamic or vascular outcomes downstream of CKD. Thus it does not directly support or contradict the proposed mechanism about CKD-driven alterations in cardiovascular risk and blood pressure response.",
          "key_findings": "Genetically higher BMI is causally associated with decreased eGFR, increased BUN, increased UACR in diabetics, and higher risk of microalbuminuria and CKD; WHR shows similar patterns. The adverse effects are driven by metabolically unhealthy obesity and, for albuminuria, additionally by type 2 diabetes. Genetically predicted kidney function was not associated with BMI or WHR (no evidence that reduced kidney function causes higher obesity). The study does not assess cardiovascular outcomes, blood pressure response, or vascular/structural changes due to CKD.",
          "pmid": "34922334",
          "title": "Obesity and Kidney Function: A Two-Sample Mendelian Randomization Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how SGLT-2 inhibitors modify cardiovascular and renal outcomes in patients with CKD, but it does not examine whether CKD itself increases cardiovascular risk or alters blood pressure responses due to vascular or structural changes. It reports outcome differences by CKD status but does not investigate or describe the underlying biological mechanisms of CKD-related vascular/structural alterations or blood pressure responses.",
          "key_findings": "In patients with CKD (eGFR <60 ml/min/1.73m\u00b2), SGLT-2 inhibitors reduced cardiovascular death (RR 0.87), heart failure (RR 0.67), CKD progression (RR 0.77), AKI (RR 0.82), and treatment discontinuation compared with placebo, and heart failure risk reduction appeared greater in CKD vs non-CKD. However, the study does not analyze or attribute these outcomes to CKD-induced vascular or structural changes or altered blood pressure responses.",
          "pmid": "37741858",
          "title": "SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "egfr",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Reduced kidney function affects drug clearance, risking drug accumulation and toxicity.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"egfr\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"accumulation\" OR \"clearance\" OR \"function\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 10.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular, kidney, and mortality outcomes and safety (hypoglycemia, retinopathy, pancreatic events) of long-acting GLP-1 receptor agonists but does not address how reduced kidney function alters drug clearance, nor does it examine drug accumulation or toxicity in the setting of impaired renal function. Kidney outcomes are clinical endpoints, not pharmacokinetic or toxicity measures.",
          "key_findings": "Long-acting GLP-1 receptor agonists (injectable and oral) in type 2 diabetes reduced major adverse cardiovascular events by 14%, hospitalization for heart failure by 14%, composite kidney outcome by 17%, and all-cause mortality by 12%, with no increased risks of severe hypoglycemia, retinopathy, or pancreatic events; no heterogeneity was found between subcutaneous and oral formulations. The study does not report on drug clearance, accumulation, or toxicity in relation to reduced kidney function.",
          "pmid": "40156846",
          "title": "Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses biologics-based immunotherapy, limitations related to enzymatic digestion, biological barriers, and rapid clearance by the reticuloendothelial system, as well as drug delivery strategies to improve immunotherapy. It does not mention kidney function, renal clearance, drug accumulation, or toxicity related to impaired renal elimination. Therefore, it neither supports nor conflicts with the proposed mechanism about reduced kidney function affecting drug clearance.",
          "key_findings": "Biologics-based immunotherapy is limited by factors such as susceptibility to enzymatic digestion, poor penetration across biological barriers, and rapid clearance by the reticuloendothelial system; drug delivery systems are reviewed as strategies to improve immunotherapeutic delivery.",
          "pmid": "33996408",
          "title": "Biological drug and drug delivery-mediated immunotherapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports on tolvaptan safety, pharmacodynamics, and efficacy in pediatric ADPKD patients with preserved kidney function (eGFR \u226560 ml/min/1.73 m\u00b2), but it does not assess how reduced kidney function alters tolvaptan clearance, drug accumulation, or toxicity risk. No measurements of pharmacokinetics in relation to varying levels of renal function, nor any analysis of drug accumulation with impaired kidney function, are presented.",
          "key_findings": "Children and adolescents with ADPKD (eGFR \u226560) were randomized to tolvaptan or placebo with weight-based titration. Tolvaptan showed expected pharmacodynamic effects (greater reductions in urine osmolality and specific gravity vs placebo) and a numerically smaller increase in height-adjusted total kidney volume over 12 months. Aquaretic adverse events were more common with tolvaptan (65% vs 16%), with low rates of hypernatremia (2% vs 0%) and no reported liver injury. The trial did not investigate altered drug clearance or accumulation due to reduced renal function.",
          "pmid": "36719158",
          "title": "Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the renal effects, proteinuria, and safety of dapagliflozin in CKD patients, but does not study drug clearance, pharmacokinetics, or toxicity as a function of reduced kidney function. Although it reports changes in measured GFR and adverse events, it does not evaluate whether impaired kidney function alters dapagliflozin clearance or leads to drug accumulation or toxicity, so it neither supports nor contradicts the proposed pharmacokinetic mechanism.",
          "key_findings": "In non-diabetic CKD patients (mean measured GFR ~58 mL/min/1.73 m\u00b2), 6 weeks of dapagliflozin compared with placebo: (1) did not significantly change 24-hour proteinuria (difference 0.9%, 95% CI -16.6 to 22.1; p=0.93); (2) caused an acute, reversible decline in measured GFR of -6.6 mL/min/1.73 m\u00b2 (p<0.0001) that resolved after discontinuation; (3) reduced bodyweight by 1.5 kg (p=0.046); (4) had similar overall adverse event rates to placebo and no hypoglycemic events. No pharmacokinetic measurements, drug levels, or evidence of drug accumulation or specific toxicity related to reduced kidney function were reported.",
          "pmid": "32559474",
          "title": "Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical outcomes and safety of SGLT2 inhibitors in people with CKD and diabetes but does not assess how reduced kidney function alters drug clearance or causes drug accumulation/toxicity. There is no pharmacokinetic data, no analysis of dose adjustment by level of kidney function, and no evidence about drug levels in relation to renal impairment.",
          "key_findings": "SGLT2 inhibitors in CKD with diabetes reduce all-cause and cardiovascular death, kidney failure, and some cardiovascular outcomes, with less hypoglycaemia versus placebo. Effects on eGFR, amputation, and fracture are uncertain. The review does not report on drug clearance, accumulation, or toxicity profiles specifically in relation to degree of reduced kidney function.",
          "pmid": "38770818",
          "title": "Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates renal outcomes (eGFR decline, ESRD, renal death) and shows that dapagliflozin slows progression of kidney disease, but it does not discuss drug pharmacokinetics, clearance, accumulation, or toxicity in the context of reduced kidney function. Therefore it neither supports nor contradicts the specific pharmacological mechanism about impaired renal drug clearance leading to accumulation and toxicity.",
          "key_findings": "Participants had creatinine clearance \u226560 mL/min at inclusion; dapagliflozin reduced cardiorenal and renal-specific composite outcomes vs placebo (HR 0.76 and 0.53, respectively) and reduced sustained eGFR decline and risk of ESRD or renal death. Early eGFR dip with later preservation was observed. No data are presented on how reduced kidney function alters dapagliflozin clearance or causes drug accumulation or toxicity.",
          "pmid": "31196815",
          "title": "Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports on efficacy and general safety of neoadjuvant and adjuvant osimertinib in EGFR-mutant NSCLC but does not discuss kidney function, renal impairment, pharmacokinetics, drug clearance, or accumulation-related toxicity. Therefore it neither supports nor contradicts the proposed mechanism about reduced kidney function affecting drug clearance.",
          "key_findings": "In a pilot study of 25 patients with stage IA\u2013IIIA EGFR-mutant NSCLC, two cycles of neoadjuvant osimertinib followed by surgery and three years of adjuvant osimertinib yielded a 44% objective response rate, 24% major pathologic response rate, no pathologic complete responses, and no grade 3 adverse events during neoadjuvant treatment. Kidney function, renal dosing, or renal-related toxicity were not reported.",
          "pmid": "39732365",
          "title": "Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates educational and behavioral programmes for people with chronic kidney disease and diabetes, focusing on outcomes like HbA1c, lipids, knowledge, self-efficacy, and behavior change. It does not examine pharmacokinetics, drug clearance, accumulation, toxicity, or how reduced kidney function alters drug handling. Therefore it neither supports nor contradicts the proposed mechanism about impaired renal drug clearance.",
          "key_findings": "Education programmes in CKD patients with diabetes probably decrease HbA1c and may improve cholesterol levels and diabetes-related knowledge and self-management behaviors. The review found uncertain effects on outcomes such as death, serious hypoglycaemia, kidney failure, and reported no data on changes in kidney function. No data on drug clearance, accumulation, or toxicity were presented.",
          "pmid": "39171639",
          "title": "Education programmes for people with chronic kidney disease and diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly states that accurate measurement of kidney function is paramount for evaluating medication safety and effectiveness, and that eGFR equations incorporating cystatin C should be used to improve pharmacodynamic target attainment and reduce drug toxicity. This directly aligns with the mechanism that reduced kidney function alters drug clearance, leading to risk of accumulation and toxicity, and that better assessment of kidney function is needed for safe dosing.",
          "key_findings": "1) Pharmacists dose and monitor medications eliminated by or toxic to the kidney, and accurate kidney function measurement is essential for evaluating their safety and effectiveness. 2) Serum creatinine-based eGFR has limitations and may not accurately reflect kidney function. 3) Cystatin C can be used as an adjunct or alternative marker to estimate kidney function for drug dosing. 4) Use of cystatin C-based eGFR equations is recommended in scenarios where they have demonstrated improved pharmacodynamic target attainment for antibiotics or reduced drug toxicity.",
          "pmid": "32182861",
          "title": "Cystatin C: A Primer for Pharmacists.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of renal denervation on blood pressure, cardiovascular outcomes, and kidney function (serum creatinine, eGFR, creatinine clearance), but does not examine drug pharmacokinetics, drug clearance, or drug toxicity. While kidney function measures are reported as unchanged, there is no discussion of how altered renal function influences drug accumulation or toxicity, so the proposed pharmacological mechanism is neither supported nor contradicted.",
          "key_findings": "Renal denervation showed no significant effect on serum creatinine (MD 0.01 mg/dL; 95% CI -0.12 to 0.14), eGFR, or creatinine clearance (MD -2.09 mL/min; 95% CI -8.12 to 3.95), indicating no detectable change in renal function in these trials; however, no data on drug clearance, accumulation, or toxicity were reported.",
          "pmid": "28220472",
          "title": "Renal denervation for resistant hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how reduced kidney function alters drug clearance and leads to drug accumulation and toxicity. The abstract evaluates renal denervation as a treatment for resistant hypertension and reports its effects on blood pressure and kidney function metrics (serum creatinine, eGFR), but it does not address drug pharmacokinetics, drug clearance, accumulation, or toxicity. Therefore, it neither supports nor contradicts the specific pharmacological mechanism.",
          "key_findings": "Renal denervation in resistant hypertension showed little or no effect on serum creatinine (MD 0.03 mg/dL, 95% CI -0.06 to 0.13) and did not increase eGFR or creatinine clearance (MD -2.56 mL/min, 95% CI -7.53 to 2.42). The study does not examine drug levels, clearance, or toxicity.",
          "pmid": "34806762",
          "title": "Renal denervation for resistant hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke prevention in atrial fibrillation and the use of non\u2013vitamin K antagonist oral anticoagulants in various clinical scenarios, but it does not mention kidney function, renal impairment, drug clearance, or toxicity related to altered clearance. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The statement reviews evolving strategies for stroke prevention in atrial fibrillation with non\u2013vitamin K antagonist oral anticoagulants versus vitamin K antagonists, emphasizing treatment options, local availability, cost, and comorbidities, but provides no specific data or discussion about renal function affecting drug clearance or accumulation.",
          "pmid": "36624790",
          "title": "Stroke Prevention in Atrial Fibrillation: A Scientific Statement of <i>JACC: Asia</i> (Part 2).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses cisplatin pharmacokinetics, nephrotoxicity, and kidney injury biomarkers, but it does not specifically address how reduced kidney function alters cisplatin (or any drug) clearance leading to accumulation and toxicity. It focuses on AKI risk factors and the need to better understand PK\u2013toxicodynamic relationships, without presenting data or explicit claims about impaired renal function changing drug clearance.",
          "key_findings": "Cisplatin causes AKI in about 30% of patients; PK/TD models use traditional kidney function biomarkers (SCr, BUN, eGFR, CrCl). Risk factors for cisplatin nephrotoxicity include dose, age, sex, race, body surface area, genetics, concomitant medications, and comorbidities. The relationships between platinum pharmacokinetics and kidney injury biomarkers are not well elucidated, and the review calls for improved PKTD models to predict and prevent cisplatin-induced kidney injury.",
          "pmid": "39322416",
          "title": "Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how ARBs affect blood pressure, proteinuria, and renal function markers (eGFR, creatinine, creatinine clearance) in CKD patients, but it does not address drug pharmacokinetics, clearance of ARBs or other drugs, or risk of drug accumulation/toxicity due to reduced kidney function. Thus it neither supports nor contradicts the proposed pharmacological mechanism about impaired renal drug clearance.",
          "key_findings": "In CKD patients with hypertension, ARB therapy (mono- and combination) significantly reduced blood pressure and proteinuria over a median of 12 months, while eGFR, creatinine clearance, and serum creatinine showed no significant changes during the relatively short follow-up.",
          "pmid": "31392910",
          "title": "Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how baseline renal function (eGFR) modifies the cardiovascular and renal efficacy of SGLT2 inhibitors, not how reduced kidney function alters SGLT2 inhibitor clearance, accumulation, or toxicity. It focuses on outcome effectiveness across eGFR strata, not pharmacokinetics or drug levels, so it neither supports nor contradicts the proposed mechanism about impaired clearance and toxicity risk.",
          "key_findings": "Risk ratios for MACE, cardiovascular death, nonfatal MI, hospitalization for heart failure, and composite renal outcomes with SGLT2 inhibitors were not significantly related to baseline eGFR. Positive associations were seen between higher eGFR and risk of stroke and the composite of cardiovascular death and heart failure hospitalization, implying relatively greater benefit in lower eGFR patients. The protective cardiovascular and renal effects of SGLT2 inhibitors persisted across varying degrees of renal impairment. No data on drug clearance, accumulation, or toxicity by renal function were reported.",
          "pmid": "37474112",
          "title": "Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how exercise affects renal function parameters in diabetic nephropathy (e.g., creatinine, eGFR, urea, protein excretion), but it does not address drug pharmacokinetics, drug clearance, or drug accumulation/toxicity. While it involves kidney function, it does not test or comment on how reduced kidney function alters drug clearance.",
          "key_findings": "In patients with type 2 diabetic nephropathy or CKD stage 2\u20134, exercise had no effect on serum creatinine, serum cystatin C, or eGFR, but decreased urinary albumin-to-creatinine ratio, urinary protein-to-creatinine ratio, serum urea nitrogen, creatinine clearance, and urinary protein excretion, while increasing urea clearance.",
          "pmid": "36818178",
          "title": "Effect of exercise on renal function in diabetic nephropathy-a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that DOACs are largely eliminated via renal excretion and emphasizes the need for careful monitoring of renal function, particularly in patients with severe impairment or at risk of acute renal failure. It notes that use is restricted or not approved in end-stage renal disease or certain transplant settings, implying concern for altered clearance and safety. This directly aligns with the mechanism that reduced kidney function affects drug clearance and can lead to accumulation and toxicity risk.",
          "key_findings": "1) DOACs are to a large extent eliminated by renal excretion. 2) Anticoagulation decisions are challenging in patients with severe renal impairment due to limited data. 3) Careful monitoring of renal function before and after DOAC initiation is essential, especially in those at risk for acute renal failure. 4) None of the DOACs is approved in CKD patients with end-stage renal disease with or without dialysis, and they are not recommended in certain kidney transplant patients, indicating safety and clearance concerns in markedly reduced kidney function.",
          "pmid": "29582930",
          "title": "DOAC use in patients with chronic kidney disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how different everolimus trough concentrations after switching from calcineurin inhibitors affect renal function (eGFR), mortality, discontinuation, and adverse events, but it does not analyze how reduced kidney function alters everolimus clearance, nor does it assess drug accumulation or toxicity in relation to impaired renal function. Thus, it does not provide direct evidence for or against the proposed mechanism about kidney function\u2013dependent drug clearance.",
          "key_findings": "In kidney transplant recipients switched from calcineurin inhibitors to everolimus, higher everolimus trough levels were associated with increased eGFR, but with very high uncertainty (OR 1.31, 95% CI 0.10\u20139.50). Adverse events and treatment discontinuation increased after switching to everolimus, also with highly uncertain evidence and wide confidence intervals. Mortality effects could not be estimated due to few events. The study could not define an optimal everolimus trough concentration and does not support routine switching from calcineurin inhibitors to everolimus.",
          "pmid": "39985824",
          "title": "Effect of everolimus administration on renal function in renal transplant recipients: A systematic review and dose-response meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates antioxidant therapies in patients with chronic kidney disease and their effects on cardiovascular outcomes and kidney disease progression. It does not address pharmacokinetics, drug clearance, accumulation, or toxicity in the context of reduced kidney function. Therefore, it neither supports nor contradicts the specific mechanism that reduced kidney function alters drug clearance and increases risk of accumulation and toxicity.",
          "key_findings": "Antioxidant therapy in CKD showed: (1) no clear overall effect on cardiovascular or all-cause mortality; (2) possible cardiovascular benefit in dialysis patients; (3) possible reduction in progression to end-stage kidney disease and improvement in creatinine and creatinine clearance; and (4) no significant increase in serious adverse events. None of these findings relate to how reduced kidney function affects drug clearance or accumulation.",
          "pmid": "23076940",
          "title": "Antioxidants for chronic kidney disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between renal dysfunction and cognitive impairment/dementia risk, not how reduced kidney function alters drug clearance, accumulation, or toxicity. It does not measure pharmacokinetics, drug levels, or adverse drug reactions, so it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Albuminuria is associated with a 35% increased risk of cognitive impairment or dementia (OR 1.35, 95% CI 1.06\u20131.73), while reduced eGFR (<60 mL/min/1.73 m\u00b2) shows a non-significant trend toward increased risk (OR 1.28, 95% CI 0.99\u20131.65). Evidence for serum creatinine, creatinine clearance, and cystatin C is insufficient. Overall, the evidence for an association between renal dysfunction and cognitive impairment/dementia is modest. No data on drug clearance, accumulation, or toxicity are presented.",
          "pmid": "27974647",
          "title": "Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "egfr",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Patients with lower eGFR are prone to fluid overload and hypertension-related complications.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"egfr\" AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"complications\" OR \"hypertension\" OR \"patients\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 10.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports eGFR inclusion criteria, eGFR outcomes, and adverse events such as peripheral oedema and hypertension, but it does not analyze whether lower eGFR per se makes patients more prone to fluid overload or hypertension-related complications, nor does it stratify these adverse events by eGFR level. Thus it neither supports nor contradicts the proposed physiological mechanism.",
          "key_findings": "Patients with eGFR 35\u201390 mL/min/1.73 m\u00b2 were enrolled; Nefecon slowed eGFR decline compared with placebo. Peripheral oedema (17% vs 4%) and hypertension (12% vs 3%) were more common with Nefecon than placebo. No data link lower baseline eGFR to increased risk of fluid overload or hypertension-related complications.",
          "pmid": "37591292",
          "title": "Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates SGLT2 inhibitors\u2019 effects on cardiovascular, heart failure, and renal outcomes in HFrEF, including subgroup analyses by baseline eGFR, but it does not discuss fluid overload or hypertension-related complications as a function of lower eGFR. It only notes that treatment benefits were consistent across eGFR subgroups, without examining whether patients with lower eGFR are more prone to fluid overload or hypertension.",
          "key_findings": "SGLT2 inhibition reduced all-cause death (HR 0.87), cardiovascular death (HR 0.86), combined cardiovascular death or first HF hospitalization (HR 0.74), recurrent HF hospitalizations or cardiovascular death (HR 0.75), and a composite renal endpoint (HR 0.62). Pooled treatment effects were consistent across subgroups including baseline eGFR, but no analysis is presented relating low eGFR to fluid overload or hypertension-related complications.",
          "pmid": "32877652",
          "title": "SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions reduced eGFR as part of DKD diagnosis and highlights blood pressure regulation as a treatment target, but it does not discuss whether lower eGFR itself makes patients more prone to fluid overload or hypertension-related complications, nor does it present data linking degree of eGFR reduction to these outcomes.",
          "key_findings": "DKD is diagnosed based on persistent albuminuria and reduced eGFR; management includes blood pressure control and nephroprotective agents such as ACE inhibitors, ARBs, SGLT2 inhibitors, and GLP-1 receptor agonists. No explicit relationship between lower eGFR and fluid overload or hypertension-related complications is described.",
          "pmid": "39337706",
          "title": "Novel Insights into Diabetic Kidney Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions reduced eGFR as a risk factor in POEMS syndrome but does not discuss any relationship between lower eGFR and fluid overload or hypertension-related complications, nor does it describe physiological mechanisms linking them. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Reduced eGFR is listed among several clinical risk factors (along with low serum albumin, age, pleural effusion, and pulmonary hypertension) for POEMS syndrome, but no details are provided on fluid status, hypertension, or how eGFR influences these outcomes.",
          "pmid": "31012139",
          "title": "POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses IgA nephropathy, its pathogenesis, prognosis, biomarkers (including reduced GFR and hypertension), and treatments, but it does not address whether lower eGFR causally leads to greater fluid overload or hypertension-related complications. The relationship between eGFR level and fluid/ BP complications is not examined or quantified, so it neither supports nor contradicts the proposed physiological mechanism.",
          "key_findings": "Reduced GFR and hypertension are listed as biomarkers predicting adverse outcomes in IgA nephropathy, and renin-angiotensin inhibition is recommended if hypertensive or proteinuric, with SGLT2 inhibition suggested if GFR is reduced or proteinuric. However, the abstract does not describe fluid overload, nor does it link lower eGFR to increased risk of fluid overload or hypertension-related complications.",
          "pmid": "39188719",
          "title": "Contemporary review of IgA nephropathy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates effects of finerenone, empagliflozin, and their combination on albuminuria and safety (including hypotension and acute kidney injury) in CKD with type 2 diabetes, but it does not analyze outcomes related to fluid overload or hypertension complications as a function of eGFR level. It neither shows that lower eGFR patients are more prone to fluid overload or hypertension-related complications nor that they are not; thus it does not address the proposed physiological mechanism.",
          "key_findings": "Among CKD patients (eGFR 30\u201390 ml/min/1.73 m\u00b2) with type 2 diabetes and albuminuria on RAS blockade, combination therapy with finerenone plus empagliflozin produced a greater reduction in urinary albumin-to-creatinine ratio at 180 days than either drug alone. Safety events including symptomatic hypotension, acute kidney injury, and hyperkalemia leading to discontinuation were uncommon across groups. No specific data are reported on fluid overload or hypertension-related complications by eGFR strata.",
          "pmid": "40470996",
          "title": "Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on identifying genetic loci associated with eGFR and kidney function, using GWAS, risk scores, and expression/functional annotation. It does not examine clinical consequences of lower eGFR such as fluid overload or hypertension-related complications, nor does it assess physiological pathways of volume status or blood pressure regulation in patients with reduced eGFR.",
          "key_findings": "Identifies 264 genetic loci associated with eGFR (166 novel); shows that many loci are relevant to kidney function via association with blood urea nitrogen; constructs a genetic risk score for lower eGFR associated with clinically diagnosed CKD; integrates gene expression and fine-mapping to highlight candidate causal genes and variants. No data are presented on fluid overload, hypertension, or related complications in relation to lower eGFR.",
          "pmid": "31152163",
          "title": "A catalog of genetic loci associated with kidney function from analyses of a million individuals.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses eGFR as a potential risk factor for developing diabetic kidney disease but focuses only on its heterogeneous association with DKD risk and does not examine fluid overload, hypertension-related complications, or clinical consequences of lower eGFR. The proposed mechanism about patients with lower eGFR being prone to fluid overload and hypertension-related complications is not addressed.",
          "key_findings": "In a meta-analysis of 20 cohorts of type 2 diabetes patients with baseline eGFR \u226560 and normal albuminuria, several factors (age, BMI, smoking, retinopathy, HbA1c, systolic BP, HDL-C, triglycerides, UACR, and eGFR) were statistically significant risk factors for early DKD. Due to substantial heterogeneity among studies, eGFR was excluded from the final risk prediction model. The study concludes that more evidence is needed to support eGFR as a risk factor for DKD.",
          "pmid": "32198286",
          "title": "Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-Analysis of 20 Cohorts.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between IL-6 levels, CKD stage (eGFR categories), and major adverse cardiovascular events. It does not assess fluid status, volume overload, or hypertension-related complications as outcomes, nor does it examine whether lower eGFR specifically leads to fluid overload or hypertension. Therefore, it neither supports nor contradicts the proposed mechanism about fluid overload and hypertension in patients with lower eGFR.",
          "key_findings": "In a cohort of 14,611 patients with chronic coronary syndrome, higher IL-6 levels were independently associated with increased risk of major adverse cardiovascular events across all eGFR strata (normal, mildly decreased, and moderately to severely decreased). Event rates and hazard ratios for MACE were higher with IL-6 \u22652.0 ng/L vs <2.0 ng/L within each kidney function category, but no measures of fluid overload or hypertension-related complications were reported.",
          "pmid": "34431970",
          "title": "Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how SGLT2 inhibitors affect CKD progression across different baseline eGFR and albuminuria levels, but it does not analyze fluid status, hypertension, or complications related to fluid overload. While it stratifies by eGFR, it does not examine whether lower eGFR is associated with greater fluid overload or hypertension-related complications, nor does it present mechanistic data on these issues. Therefore, it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "SGLT2 inhibitors reduced the risk of CKD progression (HR ~0.62) and slowed eGFR decline across all baseline eGFR and albuminuria subgroups, including patients with stage 4 CKD and minimal albuminuria. The protective effect on kidney outcomes did not significantly differ by eGFR category (P for trend = .16) or albuminuria level (P for trend = .49). The abstract does not report outcomes related to fluid overload or hypertension complications.",
          "pmid": "41203232",
          "title": "SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related decline in GFR, nephron loss, and structural kidney changes, but it does not assess fluid status, volume overload, or hypertension-related complications in relation to lower eGFR. It only comments that age-related eGFR <60 (without albuminuria) is associated with little to no increase in mortality or ESRD, which is an outcome statement, not a direct evaluation of fluid overload or hypertension risk.",
          "key_findings": "1) Aging is associated with nephron loss and a corresponding reduction in whole-kidney GFR. 2) In the absence of albuminuria, age-related reduction in GFR with eGFR <60 ml/min/1.73 m\u00b2 is associated with very modest to no increase in age-standardized mortality risk or ESRD. 3) The abstract does not report on fluid overload, volume status, or hypertension-related complications in relation to reduced eGFR.",
          "pmid": "28790143",
          "title": "Structural and Functional Changes in Human Kidneys with Healthy Aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports on safety and efficacy of daratumumab in PGNMID, including inclusion criteria based on eGFR and outcomes of proteinuria and kidney function stabilization, but it does not assess fluid overload, hypertension, or complications specifically related to lower eGFR. Therefore, it neither supports nor contradicts the proposed mechanism about fluid overload and hypertension in patients with reduced eGFR.",
          "key_findings": "Patients enrolled had eGFR >20 ml/min/1.73 m\u00b2 and proteinuria >1 g/d. Daratumumab treatment led to partial or complete remission in all treated PGNMID patients, with significant reduction in proteinuria and stabilization of kidney function over 12 months. The study did not report on fluid status, blood pressure outcomes, or hypertension-related complications stratified by eGFR.",
          "pmid": "33685975",
          "title": "Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses patterns of eGFR decline and phenotypes of diabetic kidney disease, but it does not address fluid overload, hypertension-related complications, or how lower eGFR physiologically predisposes to these outcomes. Thus, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The abstract describes non-albuminuric DKD characterized by reduced eGFR without albuminuria, notes that eGFR decline can occur independently of albuminuria, and highlights uncertainty about which DKD phenotype has higher cardiovascular risk. It does not mention fluid overload or hypertension-related complications in relation to lower eGFR.",
          "pmid": "37238622",
          "title": "Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how sacubitril/valsartan versus enalapril affect eGFR decline, albuminuria, and cardiovascular/renal outcomes in heart failure patients, including those with chronic kidney disease. It does not analyze whether patients with lower eGFR are more prone to fluid overload or hypertension-related complications, nor does it measure fluid status or blood pressure complications as a function of baseline eGFR. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In PARADIGM-HF, baseline eGFR was 70 \u00b1 20 ml/min/1.73 m\u00b2 with 33% having chronic kidney disease. Sacubitril/valsartan slowed the decline in eGFR compared with enalapril despite causing a modestly greater increase in UACR. The beneficial effect on cardiovascular death or heart failure hospitalization was not modified by baseline eGFR, UACR, or change in UACR. Fluid overload or hypertension-related complications by eGFR level were not reported.",
          "pmid": "29655829",
          "title": "Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports on a trial of balcinrenone plus dapagliflozin in heart failure patients with moderate CKD (eGFR 30\u201360), focusing on albuminuria, eGFR changes, potassium, and NT-proBNP. It does not examine or compare rates of fluid overload, volume status, or hypertension-related complications across different eGFR levels, nor does it analyze how lower eGFR predisposes to such complications. Therefore, it neither supports nor contradicts the proposed physiological mechanism.",
          "key_findings": "In HF patients with CKD (eGFR 30\u201360), balcinrenone plus dapagliflozin did not significantly reduce UACR versus dapagliflozin plus placebo; higher doses showed possible dose-dependent increases in serum potassium and reduced eGFR, with some hyperkalaemia-related discontinuations. Fluid overload or hypertension-related complications by eGFR level were not reported.",
          "pmid": "38783712",
          "title": "Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract reports that cardiovascular and heart failure risks increase as eGFR decreases, which aligns with the idea that lower kidney function predisposes patients to adverse hemodynamic and fluid-related outcomes such as heart failure and hypertension-related complications. While the abstract does not explicitly discuss fluid overload or hypertension as mediators, the observed gradient of worsening heart failure outcomes with lower eGFR is consistent with the proposed physiological mechanism.",
          "key_findings": "1) In patients with type 2 diabetes, risks of cardiovascular mortality and heart failure increase with decreasing eGFR and increasing albuminuria. 2) The risk of outcomes increased across baseline eGFR and UACR categories, with the lowest incidences in those with eGFR \u226560 mL/min/1.73 m\u00b2 and UACR <300 mg/g. 3) These data link lower kidney function to higher heart failure and cardiovascular risk, indirectly supporting susceptibility to fluid and blood pressure\u2013related complications in patients with reduced eGFR.",
          "pmid": "36328655",
          "title": "Finerenone and Heart\u00a0Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies sacubitril/valsartan effects on cardiovascular and renal outcomes in CKD patients with eGFR <60 mL/min/1.73 m\u00b2, but it does not examine fluid status, volume overload, or hypertension-related complications as a function of lower eGFR. It neither confirms nor refutes that patients with lower eGFR are more prone to fluid overload and hypertension-related complications.",
          "key_findings": "In CKD patients (eGFR <60), sacubitril/valsartan vs ACEI/ARBs reduced cardiovascular death or heart failure hospitalization, reduced serum creatinine elevation, decreased risk of >50% eGFR reduction with long follow-up, showed a non\u2011significant trend toward reduced ESRD, increased hypotension risk, and did not increase hyperkalemia risk. Fluid overload or blood pressure complications specifically related to lower eGFR were not assessed.",
          "pmid": "37195574",
          "title": "The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on methods for accurately estimating GFR (eGFR equations, cystatin C use, and measured GFR) in cancer patients and their implications for drug dosing and eligibility. It does not address physiological outcomes such as fluid overload, hypertension, or their relationship to lower eGFR.",
          "key_findings": "The statement emphasizes the importance of accurate GFR assessment in cancer patients, reviews performance of CKD-EPI creatinine and creatinine\u2013cystatin C equations against measured GFR, notes that many cancer patients have CKD, and advocates for using validated equations and measured GFR for borderline therapeutic decisions. No data are presented linking lower eGFR with fluid overload or hypertension-related complications.",
          "pmid": "38848131",
          "title": "Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that empagliflozin slows eGFR decline and improves heart failure outcomes in patients with preserved ejection fraction, with similar effects regardless of atrial fibrillation status. It does not analyze the relationship between lower eGFR and risk of fluid overload or hypertension-related complications, nor does it stratify outcomes by baseline eGFR or examine fluid status or blood pressure consequences of reduced eGFR.",
          "key_findings": "Empagliflozin reduced cardiovascular death or heart failure hospitalization and total heart failure hospitalizations, and slowed annual eGFR decline, in patients with HF and LVEF >40%, with similar benefits in those with and without atrial fibrillation. No increase in serious adverse events was observed. The study does not evaluate fluid overload or hypertension-related complications as a function of lower eGFR.",
          "pmid": "37062866",
          "title": "Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract shows that patients whose eGFR deteriorated to <30 mL/min/1.73 m\u00b2 had substantially higher risk of cardiovascular death or heart failure hospitalization compared with those without such deterioration. In heart failure, these outcomes are closely linked to fluid overload and hypertension-related complications. Thus, worsening renal function (lower eGFR) is associated with worse cardiorenal outcomes, consistent with the mechanism that patients with lower eGFR are more prone to such complications, even though fluid overload and blood pressure are not measured directly.",
          "key_findings": "Among 4,355 HF patients, 295 whose eGFR declined to <30 mL/min/1.73 m\u00b2 had more impaired baseline kidney and cardiac function and a higher risk of cardiovascular death or HF hospitalization (HR 2.49; 95% CI 2.01\u20133.08) than patients without eGFR deterioration, indicating that lower eGFR is associated with markedly worse HF-related outcomes.",
          "pmid": "38739064",
          "title": "Mineralocorticoid Receptor Antagonists in Patients With Heart\u00a0Failure and Impaired\u00a0Renal\u00a0Function.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbp",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Low DBP can impair coronary perfusion, especially in coronary artery disease patients.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"dbp\" AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"especially\" OR \"perfusion\" OR \"coronary\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 6,
      "conflict_count": 1,
      "neutral_count": 13,
      "support_percentage": 30.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.3,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses lifestyle management of hypertension and general cardiovascular risk but does not address diastolic blood pressure being too low, coronary perfusion, or coronary artery disease\u2013specific consequences of low DBP. No mechanistic or outcome data related to impaired coronary perfusion at low DBP are presented.",
          "key_findings": "Defines hypertension thresholds (SBP >140 mmHg and/or DBP \u226590 mmHg), notes its association with increased CVD risk, and summarizes lifestyle interventions (weight control, physical activity, diet, smoking/alcohol avoidance, stress and sleep management). Does not discuss effects of low DBP or coronary perfusion.",
          "pmid": "37712135",
          "title": "Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the blood pressure\u2013lowering efficacy and safety of renal denervation but does not examine coronary perfusion, diastolic blood pressure thresholds, or outcomes specifically in coronary artery disease patients. It reports average DBP reductions and safety endpoints (death, vascular complications, renal artery stenosis, hypertensive crisis), but does not link low DBP levels to impaired coronary perfusion or related clinical events.",
          "key_findings": "Renal denervation in randomized sham-controlled trials reduced 24-hour DBP by about 2.6 mmHg and office DBP by about 3.5 mmHg versus sham, with no significant differences in vascular complications, renal artery stenosis, hypertensive crisis, all-cause death, or change in eGFR. The analysis does not assess coronary perfusion, ischemic events, or specific risks of low DBP, particularly in patients with coronary artery disease.",
          "pmid": "39355923",
          "title": "Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that HIIT vs MICT increases diastolic blood pressure (DBP) by ~3.4 mmHg in coronary artery disease patients, but it does not examine coronary perfusion, ischemia, angina, myocardial outcomes, or any adverse effects specifically attributable to low DBP. Thus it neither tests nor links low DBP with impaired coronary perfusion, and so does not provide direct support or conflict for the proposed mechanism.",
          "key_findings": "In a meta-analysis of 22 RCTs (n=1364) in coronary artery disease patients, HIIT compared with MICT significantly increased DBP (WMD = 3.43 mmHg, 95% CI 1.09\u20135.76), along with improvements in PeakVO2, 6MWT distance, and peak heart rate, with no significant differences in LVEF, LVEDV, or SBP. No outcomes related to coronary perfusion impairment due to low DBP were reported.",
          "pmid": "39977401",
          "title": "Effects of high-intensity interval training versus moderate-intensity continuous training on cardiorespiratory and exercise capacity in patients with coronary artery disease: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that reduction of diastolic blood pressure (DBP) below ~70 mmHg may decrease perfusion to the heart and reports that achieved DBP <60 mmHg is associated with higher risk of myocardial infarction and major adverse cardiovascular events, especially in patients with pre-existing cardiovascular disease. This aligns with the proposed mechanism that low DBP can impair coronary perfusion and worsen outcomes in coronary artery disease patients.",
          "key_findings": "In a meta-analysis of 10 studies including 1,998,223 patients, mean achieved DBP <60 mmHg was associated with increased all-cause mortality (HR 1.48; 95% CI 1.26\u20131.74), particularly in patients with pre-existing cardiovascular disease, and with higher risk of major adverse cardiovascular events (HR 1.84; 95% CI 1.28\u20132.65) and myocardial infarction (HR 1.49; 95% CI 1.13\u20131.97). DBP 60\u201369 mmHg was also associated with increased all-cause mortality (HR 1.11; 95% CI 1.03\u20131.20). The authors frame these findings in the context that DBP reduction below 70 mmHg may decrease perfusion to the heart and worsen cardiovascular outcomes.",
          "pmid": "37866417",
          "title": "Association of low diastolic blood pressure with cardiovascular outcomes and all-cause mortality: A meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses high\u2011intensity interval training effects on general blood pressure, arterial compliance, and vascular/cardiac function, but provides no data on diastolic blood pressure levels, low DBP, or coronary perfusion, nor does it analyze risks specifically in coronary artery disease patients related to low DBP.",
          "key_findings": "HIIT improves cardiorespiratory fitness, arterial compliance and vascular function, cardiac function, and blood pressure in various populations, and appears safe without serious cardiovascular events, but the abstract does not report DBP-specific effects, thresholds of low DBP, or coronary perfusion outcomes.",
          "pmid": "31889469",
          "title": "Can high-intensity interval training improve physical and mental health outcomes? A meta-review of 33 systematic reviews across the lifespan.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that in the presence of severe coronary artery stenosis and/or LVH, a fall in diastolic blood pressure (coronary perfusion pressure) leads to a fall in coronary flow, ECG changes, and ventricular dysfunction, and links this to increased myocardial infarction in CAD/LVH patients when DBP is lowered below the low\u2013mid 80s. This directly supports the mechanism that low DBP can impair coronary perfusion, particularly in coronary artery disease patients.",
          "key_findings": "1) Coronary flow is normally autoregulated over a wide range of perfusion pressures approximating diastolic BP. 2) Coronary flow reserve is markedly impaired in severe coronary artery stenosis and/or LVH. 3) In the presence of severe stenosis and LVH, a fall in DBP that would normally be tolerated instead results in reduced coronary flow, ECG changes, and decreased ejection fraction. 4) Lowering DBP below the low\u2013mid 80s in patients with CAD and LVH increases the frequency of myocardial infarction, explaining a J-curve relationship between DBP and MI in high-risk hypertensives.",
          "pmid": "1396858",
          "title": "The role of coronary perfusion pressure.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that in patients with coronary artery disease (limited coronary flow reserve) there is a J-curve relationship between treated diastolic blood pressure and myocardial infarction, and recommends avoiding lowering DBP below the low 80s mm Hg. This directly supports the mechanism that low DBP can impair coronary perfusion and increase ischemic events in coronary artery disease patients.",
          "key_findings": "In nonischemic hypertensive subjects, lowering DBP to the low 80s mm Hg is beneficial and going lower is safe but unproductive. However, in patients with coronary artery disease (limited coronary flow reserve), there is a J-curve relationship between treated DBP and myocardial infarction (but not stroke), and the authors advise avoiding lowering DBP below the low 80s mm Hg.",
          "pmid": "14558984",
          "title": "The J-curve in hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract assesses effects of bedtime vs. morning low-dose aspirin on blood pressure levels and platelet aggregation, but does not examine coronary perfusion, ischemia, or clinical outcomes related to low diastolic blood pressure, particularly in coronary artery disease patients. It reports no significant change in DBP in treated hypertension/CVD patients, yet does not link DBP levels to coronary perfusion or adverse events, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Bedtime aspirin lowered systolic and diastolic blood pressure in prehypertension/untreated hypertension (DBP MD \u22124.02 mmHg, 95% CI \u22125.94 to \u22122.11) but showed no significant DBP difference in treated hypertension and cardiovascular disease subgroup (DBP MD \u22120.46 mmHg, 95% CI \u22122.20 to 1.28). The study also found reduced platelet aggregation with bedtime aspirin. No assessment of coronary perfusion or ischemic outcomes related to low DBP is provided.",
          "pmid": "40065523",
          "title": "Bedtime vs. morning aspirin intake on the diurnal variability of blood pressure and platelet aggregation for the prevention of coronary artery diseases: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular risk associated with stage 1 hypertension (including elevated DBP 80\u201389 mmHg) versus normal blood pressure, but it does not examine low diastolic blood pressure, coronary perfusion, or outcomes in patients with existing coronary artery disease. Therefore it does not address whether low DBP impairs coronary perfusion.",
          "key_findings": "Stage 1 hypertension (SBP 130\u2013139 mmHg or DBP 80\u201389 mmHg) was associated with increased risk of overall CVD events (HR 1.38), CHD (HR 1.30), stroke (HR 1.39), CVD morbidity (HR 1.42), and CVD mortality (HR 1.34) compared with normal BP (SBP <120 mmHg and DBP <80 mmHg). The study estimated that effective control of stage 1 hypertension could prevent over 10% of CVD events.",
          "pmid": "31790053",
          "title": "Stage 1 hypertension by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and risk of cardiovascular disease events: systematic review, meta-analysis, and estimation of population etiologic fraction of prospective cohort studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that chronic resistance training slightly reduces both systolic and diastolic blood pressure and that post-exercise hypotension occurs, but it does not discuss diastolic pressure thresholds, coronary perfusion physiology, or clinical outcomes related to low DBP, especially in coronary artery disease patients. Thus it neither supports nor contradicts the specific mechanism that low DBP can impair coronary perfusion.",
          "key_findings": "1) Chronic resistance training is associated with slight reductions in resting SBP and DBP. 2) A single resistance exercise bout can induce post-exercise hypotension in normal and hypertensive individuals. 3) Cardiovascular stability is observed in patients with coronary disease or heart failure during resistance exercise, with no apparent detriment to ventricular function or exaggerated exercise blood pressure response. 4) The abstract does not address whether reduced DBP from these interventions impairs coronary perfusion or worsens outcomes in coronary artery disease.",
          "pmid": "17992383",
          "title": "Hemodynamic and vascular effects of resistance training: implications for cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract directly reports that, in middle\u2011aged and older subjects with SBP \u2265120 mmHg, coronary heart disease risk rose when diastolic blood pressure was discordantly lower, implying that lower DBP is associated with higher CHD risk in this context. This aligns with the proposed mechanism that low DBP can impair coronary perfusion, particularly in individuals likely to have coronary artery disease.",
          "key_findings": "In subjects aged \u2265 middle age, after age 50\u201360 DBP declined while PP rose; after adjustment for age, sex, and other risk factors, pulse pressure was superior to SBP as a predictor of CHD risk in the presence of discordantly low DBP. Specifically, for any given SBP \u2265120 mmHg, CHD risk increased as DBP decreased, indicating that discordantly low DBP (wider PP) is associated with higher CHD risk.",
          "pmid": "10706323",
          "title": "Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that isometric resistance training reduces diastolic blood pressure, including in a sample where some participants have coronary artery disease, but it does not assess coronary perfusion, ischemic outcomes, or adverse events related to low DBP. It neither tests nor discusses whether the DBP reduction impairs coronary perfusion, so it does not provide direct evidence for or against the proposed mechanism.",
          "key_findings": "In an individual participant data meta-analysis of 12 trials (326 participants; 25.2% with coronary artery disease), isometric resistance training reduced resting DBP by about 2.8\u20133.3 mmHg, SBP by about 6\u20137 mmHg, and MAP by about 4\u20135 mmHg. Treatment effects were not modified by clinical characteristics (including coronary artery disease), medications, demographics, or exercise-program features. No data on coronary perfusion or ischemic outcomes are reported.",
          "pmid": "30889048",
          "title": "Effects of isometric resistance training on resting blood pressure: individual participant data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly links acute lowering of diastolic blood pressure to reduced coronary blood flow, ischemic ECG changes, and worse ventricular functional reserve in patients with coronary artery disease plus left ventricular hypertrophy, and describes a U/J-shaped relationship between DBP and CAD deaths with increased risk at lower DBP in high\u2011risk (ischemic/CAD, LVH) populations. This directly supports the mechanism that low DBP can impair coronary perfusion particularly in patients with coronary artery disease.",
          "key_findings": "1) In patients with severe LVH but no significant CAD, acute lowering of DBP to <85 mm Hg resulted in a 26% fall in coronary blood flow and ischemic ECG changes when DBP was lowered into the 70s. 2) In patients with CAD or LVH and good LV function, lowering DBP to the 60s increased ejection fraction by ~20%, but in patients with combined CAD and LVH, the same DBP reduction led to a mean 6% fall in ejection fraction, implying poor LV reserve. 3) In low-risk populations (excluding severe ischemia, diabetics, smokers), lower DBP was associated with fewer myocardial infarctions, whereas in heterogeneous hypertensive populations including high\u2011risk ischemic and diabetic patients, a strong U- or J-curve between DBP and CAD deaths was observed, with the nadir around 84 mm Hg. 4) Framingham data showed that patients with both CAD and LVH had a marked U-shaped curve for risk with a DBP J-point around 85\u201389 mm Hg, indicating increased CAD risk at lower DBP in this group, consistent with impaired coronary perfusion at low DBP in CAD patients.",
          "pmid": "1301256",
          "title": "Clinical importance of coronary perfusion pressure in the hypertensive patient with left ventricular hypertrophy.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly reports that in the ONTARGET study, at any level of achieved systolic blood pressure, a diastolic blood pressure below 67 mm Hg was associated with increased risk for cardiovascular outcomes in diabetic patients, who are highly associated with underlying coronary artery disease. The authors then recommend keeping DBP above 60 mm Hg in diabetics with coronary artery disease, consistent with the mechanism that low DBP can impair coronary perfusion and worsen outcomes.",
          "key_findings": "1) In ONTARGET, among diabetic patients, diastolic blood pressure below 67 mm Hg was associated with increased risk for cardiovascular outcomes at any achieved systolic blood pressure level. 2) Because diabetes is highly associated with underlying coronary artery disease and there is concern about adverse effects from excessive BP lowering, the authors recommend targeting a DBP above 60 mm Hg in diabetics with coronary artery disease. 3) These findings are presented in the context of potential harm from overly low blood pressure, consistent with impaired coronary perfusion at low DBP.",
          "pmid": "27593856",
          "title": "Target Blood Pressure in Patients with Diabetes: Asian Perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure patterns in the elderly, isolated systolic hypertension, and cardiovascular risk, but it does not address whether low diastolic blood pressure impairs coronary perfusion or outcomes, nor does it analyze this specifically in patients with coronary artery disease.",
          "key_findings": "The paper states that systolic blood pressure is more dangerous than diastolic blood pressure in elderly hypertensives and defines isolated systolic hypertension (SBP >140 with DBP <90), but provides no data or discussion on the physiological impact of low diastolic pressure on coronary perfusion, particularly in CAD patients.",
          "pmid": "10652909",
          "title": "Hypertension in elderly--an overview.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that higher diastolic blood pressure time in target range (DBP-TTR) is associated with better cardiovascular outcomes and that low DBP-TTR attenuates the benefit of good systolic control, but it does not specifically examine low absolute DBP levels, coronary perfusion physiology, or differentiate effects in patients with versus without coronary artery disease. Thus, it addresses BP control and outcomes broadly rather than directly testing whether low DBP impairs coronary perfusion, especially in CAD patients.",
          "key_findings": "1) Both higher systolic and diastolic BP time in target range (SBP-TTR and DBP-TTR) were associated with reduced risk of a composite cardiovascular outcome (nonfatal MI, acute coronary syndromes, stroke, acute decompensated heart failure, and cardiovascular death) in hypertensive patients with pre-frailty or frailty. 2) Restricted cubic spline analyses suggested a linear association between higher BP-TTR and lower risk of primary outcomes. 3) Subgroup analyses indicated that the protective effect of higher SBP-TTR was less pronounced in the setting of low DBP-TTR, implying that inadequate diastolic control may diminish benefit, but without explicitly linking low DBP to impaired coronary perfusion or focusing on CAD-specific physiology.",
          "pmid": "38552135",
          "title": "Systolic and diastolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension and pre-frailty or frailty status.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that diastolic blood pressure (DBP) is a causal determinant of migraine risk in subtype-specific analyses, but it does not examine coronary perfusion, coronary artery disease patients, or the physiological consequences of low DBP on coronary circulation. Therefore, it neither supports nor contradicts the proposed mechanism regarding low DBP impairing coronary perfusion in CAD.",
          "key_findings": "Subtype-specific Mendelian randomization analyses indicate that DBP (along with pulse pressure, serum calcium, IGF\u20111) is a causal factor influencing migraine without aura. No data are presented on coronary perfusion, diastolic pressure thresholds, or outcomes in coronary artery disease patients.",
          "pmid": "40994718",
          "title": "Causal factors for migraine in Mendelian randomization studies: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism focuses on low diastolic blood pressure (DBP) impairing coronary perfusion. This meta-analysis directly reports that zinc supplementation had no noticeable effects on DBP or SBP. Since the abstract suggests zinc does not meaningfully change DBP, it indirectly conflicts with any implication that zinc would affect coronary perfusion via altering DBP. However, it does not directly test coronary perfusion or outcomes in low-DBP or CAD patients, so the conflict is indirect.",
          "key_findings": "In a meta-analysis of 75 RCTs, zinc supplementation significantly improved several cardiovascular risk markers but showed no noticeable effects on systolic blood pressure (SBP) or diastolic blood pressure (DBP).",
          "pmid": "37399684",
          "title": "Zinc supplementation and cardiovascular disease risk factors: A GRADE-assessed systematic review and dose-response meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes the design and aims of the INTERMAP study to examine dietary influences on systolic and diastolic blood pressure, but it does not report any results on diastolic blood pressure levels, coronary perfusion, or outcomes in coronary artery disease patients. It therefore neither supports nor contradicts the specific mechanism that low diastolic blood pressure can impair coronary perfusion in CAD patients.",
          "key_findings": "The study aims to relate multiple nutrients and urinary metabolites to SBP/DBP using cross-sectional data from 4680 adults, but no specific associations, thresholds of low DBP, or coronary perfusion/coronary artery disease outcomes are reported in this abstract.",
          "pmid": "13679950",
          "title": "INTERMAP: background, aims, design, methods, and descriptive statistics (nondietary).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the impact of music therapy on anxiety and on heart rate, systolic, and diastolic blood pressure during angiography, but it does not address coronary perfusion, the physiological consequences of having low diastolic blood pressure, or outcomes specifically related to impaired coronary blood flow. It only reports that music did not significantly change DBP, rather than studying effects of low DBP on coronary perfusion.",
          "key_findings": "In angiography patients, music therapy significantly reduced anxiety (improved STAI scores) but produced no significant changes in heart rate, systolic blood pressure, or diastolic blood pressure compared with controls.",
          "pmid": "30415224",
          "title": "Effects of music therapy on anxiety and physiologic parameters in angiography: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbp",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "DBP variability and levels influence cardiovascular outcomes and mortality independently.",
        "evidence_level": "moderate"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"dbp\" AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"cardiovascular\" OR \"independently\" OR \"variability\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 3,
      "conflict_count": 1,
      "neutral_count": 16,
      "support_percentage": 15.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.15,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial evaluates the effect of ultrasound renal denervation on blood pressure levels (primarily systolic) over 2 months and reports safety outcomes, but it does not analyze diastolic blood pressure (DBP) variability, nor does it examine the independent relationship of DBP levels or their variability with cardiovascular outcomes or mortality. Therefore, it does not provide direct evidence for or against the proposed mechanism.",
          "key_findings": "Ultrasound renal denervation significantly reduced daytime ambulatory systolic blood pressure compared with sham in patients with hypertension, with improvements across multiple blood pressure measures and no major adverse events reported. DBP parameters were listed as secondary outcomes but no detailed DBP or variability\u2013outcome relationships were presented, and cardiovascular outcomes or mortality were not assessed as endpoints in relation to DBP.",
          "pmid": "36853250",
          "title": "Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study reports that the DASH diet reduced both systolic and diastolic blood pressure along with other cardiovascular risk factors in subjects with metabolic syndrome, but it does not analyze diastolic blood pressure (DBP) variability, nor does it link DBP levels or their variability to cardiovascular outcomes or mortality. Thus, it does not specifically test whether DBP variability and levels independently influence cardiovascular outcomes or mortality.",
          "key_findings": "In a randomized controlled trial of 59 subjects with metabolic syndrome, the DASH diet versus a control healthy diet produced significantly greater reductions in DBP (\u22125.16 \u00b1 3.92 vs. \u22121.50 \u00b1 7.04 mmHg; P = 0.01) and SBP (\u22126.97 \u00b1 8.21 vs. \u22121.36 \u00b1 6.83 mmHg; P = 0.006), along with improvements in fatty liver indices (FLI, HSI), anthropometrics (WC, weight, BMI), and lipid parameters (TG, TC, LDL-c). No data on DBP variability or on cardiovascular events/mortality were reported.",
          "pmid": "39054440",
          "title": "The effect of dietary approaches to stop hypertension (DASH) diet on fatty liver and cardiovascular risk factors in subjects with metabolic syndrome: a randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism states that diastolic blood pressure (DBP) levels (and variability, though variability is not addressed here) influence cardiovascular outcomes and mortality independently. This meta-analysis reports that DBP is a significant predictor for stroke but not significantly associated with all-cause mortality, while systolic BP is. Thus, for mortality outcomes, the abstract contradicts the proposed mechanism of an independent DBP effect. For stroke, it supports an independent DBP association, but the mechanism includes mortality as well, making the overall evidence partially conflicting.",
          "key_findings": "In this systematic review and meta-analysis, both systolic BP (SBP) and diastolic BP (DBP) were significant predictors for stroke: DBP pooled HR 1.056 (95% CI 1.038\u20131.074, P<0.001). For all-cause mortality, SBP was significantly associated (pooled HR 1.008, 95% CI 1.002\u20131.014, P=0.012) but DBP was not (pooled HR 1.023, 95% CI 0.964\u20131.085, P=0.451). Pulse pressure was an independent risk factor for stroke but not for mortality.",
          "pmid": "26902972",
          "title": "Pulse pressure as an independent predictor of stroke: a systematic review and a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on pulse pressure and heart rate as independent predictors of cardiovascular risk and notes that standard antihypertensive agents reduce SBP and PP less than DBP. It does not analyze diastolic blood pressure variability or DBP levels as independent determinants of cardiovascular outcomes or mortality, nor does it quantify DBP-outcome relationships separate from SBP/PP. Thus it does not directly support or refute the proposed mechanism regarding independent effects of DBP variability and levels.",
          "key_findings": "1) In normotensive and hypertensive populations, increased pulse pressure is an independent predictor of myocardial infarction, more powerful than systolic blood pressure, including in treated hypertensives.\n2) Increased heart rate is an additional cardiovascular risk factor, particularly via an enhanced pulse pressure \u00d7 heart rate product.\n3) Standard antihypertensive agents are reported to reduce systolic blood pressure and pulse pressure to a much lesser extent than diastolic blood pressure, motivating trials with drugs targeting SBP, PP, and arterial stiffness.",
          "pmid": "15128470",
          "title": "Pulse pressure, heart rate, and drug treatment of hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how PM2.5 exposure affects systolic and diastolic blood pressure levels, including some analysis of modifiers of the PM2.5\u2013DBP relationship, but it does not assess whether DBP variability or DBP levels independently influence cardiovascular outcomes or mortality. It focuses on determinants of BP, not on BP as an independent predictor of cardiovascular endpoints.",
          "key_findings": "Exposure to PM2.5 was associated with increases in SBP (1.393 mmHg per 10 \u03bcg/m\u00b3) and DBP (0.895 mmHg per 10 \u03bcg/m\u00b3). Long-term exposure showed the strongest associations, and short-term effects were largest at a 5\u2011day lag. Meta-regression identified factors (study design, BP monitoring method, publication year, study period, sample size) that modified the PM2.5\u2013DBP relationship, but no cardiovascular outcomes or mortality endpoints were analyzed.",
          "pmid": "25250520",
          "title": "Effect of exposure to PM2.5 on blood pressure: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the effects of different exercise modalities (HIIT vs MICT) on central and peripheral blood pressure levels and related parameters, not on the relationship between diastolic blood pressure (DBP) variability/levels and cardiovascular outcomes or mortality. It reports no significant differences in central or peripheral DBP between training types, but does not analyze DBP as an independent predictor of outcomes or its variability, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In a meta-analysis of six RCTs (163 patients), HIIT compared to MICT reduced central systolic BP (MD \u22123.12 mmHg) and peripheral systolic BP (MD \u22122.67 mmHg) and increased VO2max, with no significant differences for central diastolic BP, peripheral diastolic BP, or pulse wave velocity. Cardiovascular events or mortality were not assessed.",
          "pmid": "37098987",
          "title": "Effects of High-Intensity Interval Training on Central Blood Pressure: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines whether being born small for gestational age among preterm infants is associated with higher later-life blood pressure (including DBP), and finds no meaningful differences. It does not analyze DBP variability, nor whether DBP levels independently influence cardiovascular outcomes or mortality. Thus, it neither supports nor conflicts with the proposed mechanism about DBP variability/levels and cardiovascular outcomes.",
          "key_findings": "In a meta-analysis of 25 studies of preterm infants, being small for gestational age was not associated with higher later-life systolic or diastolic blood pressure (mean differences for SBP and DBP both 0.01 mmHg with 95% CI -0.10 to 0.12). Adjustment for current weight did not change results. No cardiovascular outcomes or mortality endpoints, nor blood pressure variability measures, were assessed.",
          "pmid": "36688258",
          "title": "Small for date preterm infants and risk of higher blood pressure in later life: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract reports that time-averaged cumulative DBP (and SBP) shows a U-shaped association with multiple cardiovascular outcomes, with increased risk at both lower and higher DBP ranges (outside 70\u201379 mmHg) after multivariable adjustment. This indicates that DBP level itself independently influences cardiovascular events and mortality, consistent with the proposed mechanism that DBP characteristics (here, long-term levels) affect cardiovascular outcomes independently. Although variability per se is not analyzed, the independence and directional influence of DBP levels on outcomes is directly supported.",
          "key_findings": "In 3330 HFpEF patients from TOPCAT followed for a median of 3 years, time-averaged cumulative BP (mmHg-years, converted to mmHg) was associated with primary endpoint, all-cause death, cardiovascular death, and HF hospitalization. Restricted cubic spline analyses showed a U-shaped relationship between time-averaged cumulative DBP and these outcomes, with nadir risk at 70\u201379 mmHg DBP, and significantly higher risk at both lower and higher DBP values after adjustment for confounders. The association was not significantly altered by spironolactone treatment and remained robust in sensitivity analyses.",
          "pmid": "36018222",
          "title": "Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports average pre\u2013post changes in diastolic blood pressure (DBP) after Diabetes Prevention Program lifestyle interventions, but it does not analyze DBP variability, nor does it examine the independent influence of DBP levels or their variability on cardiovascular outcomes or mortality. It focuses on risk factor changes, not outcomes or independent statistical effects, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In pooled DPP lifestyle interventions, mean DBP decreased by 2.56 mmHg (95% CI: -3.40, 1.71), alongside improvements in weight, HbA1c, fasting glucose, systolic blood pressure, HDL, and total cholesterol. The study does not assess DBP variability, cardiovascular outcomes, or mortality, and does not evaluate the independent effect of DBP metrics on such outcomes.",
          "pmid": "27459705",
          "title": "Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns whether DBP variability and DBP levels independently influence cardiovascular outcomes and mortality. This abstract evaluates how renal denervation affects BP variability and whether baseline BP variability predicts BP reduction after the procedure. It does not assess clinical cardiovascular outcomes or mortality, nor does it test the independent prognostic impact of DBP variability or levels. Thus, it neither supports nor contradicts the specific mechanistic claim about outcomes.",
          "key_findings": "In 167 patients with treatment-resistant hypertension undergoing renal denervation, mean office and 24\u2011h BP decreased significantly at 6 months. Systolic and diastolic weighted SD and VIM of 24\u2011h BP decreased, while ARV and coefficient of variation did not change significantly. Baseline DBP variability metrics (SDiw, ARV, VIM) predicted the magnitude of 24\u2011h DBP reduction after renal denervation, but there is no reporting of cardiovascular events or mortality or of variability\u2019s independent effect on such outcomes.",
          "pmid": "29045339",
          "title": "Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns overall diastolic blood pressure (DBP) levels and DBP variability as independent determinants of cardiovascular outcomes and mortality. This abstract instead focuses on orthostatic changes (difference between standing and seated BP) in both systolic and diastolic pressures, and their U-shaped association with MACE, as well as interaction with intensive BP management. It does not analyze visit\u2011to\u2011visit DBP variability, long-term DBP levels, or their independent prognostic value apart from orthostatic response, so it neither directly supports nor contradicts the broader mechanism.",
          "key_findings": "In a post hoc SPRINT analysis (n=9329), baseline orthostatic BP change (standing minus seated) for both SBP and DBP showed a U-shaped association with major adverse cardiovascular events (MACE), with lowest risk around 0 mm Hg. On one side of the inflection point, MACE risk decreased with decreasing orthostatic BP change; on the other side, MACE risk increased with increasing orthostatic BP change. Orthostatic DBP increase and SBP decrease were associated with increased MACE risk. There was no significant interaction between orthostatic SBP or DBP changes and intensive BP management, and the benefits of intensive BP control were consistent across orthostatic BP change ranges.",
          "pmid": "36007937",
          "title": "Relationship between orthostatic blood pressure changes and intensive blood pressure management in patients with hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that Baduanjin exercise lowers mean systolic and diastolic blood pressure and notes very low-certainty evidence for effects on cardiovascular morbidity and mortality, but it does not analyze diastolic blood pressure variability, independence of DBP effects from other factors, or statistical relationships between DBP levels/variability and cardiovascular outcomes. Thus it neither supports nor contradicts the proposed mechanism about DBP variability and levels independently influencing cardiovascular outcomes and mortality.",
          "key_findings": "Meta-analysis of 14 RCTs (1058 patients) found Baduanjin reduced mean SBP by 8.52 mmHg and mean DBP by 4.65 mmHg compared with routine treatment or health education. Evidence certainty for blood pressure was rated low, and for cardiovascular morbidity and mortality very low, with no direct analysis of how DBP levels or their variability independently affect cardiovascular outcomes or mortality.",
          "pmid": "33032580",
          "title": "The effectiveness of Baduanjin exercise for hypertension: a systematic review and meta-analysis of randomized controlled trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that tea intake modestly lowers systolic and diastolic blood pressure and lipids, but it does not analyze blood pressure variability, does not isolate diastolic blood pressure effects from other factors, and does not link DBP levels or variability independently to cardiovascular outcomes or mortality. Thus it does not directly address the proposed statistical mechanism.",
          "key_findings": "In RCTs totaling 821 participants, black tea reduced SBP by ~1.85 mmHg and DBP by ~1.27 mmHg (the latter not clearly statistically significant), and green tea reduced SBP by ~3.18 mmHg and DBP by ~3.42 mmHg, alongside reductions in LDL and total cholesterol. No cardiovascular events or mortality outcomes were reported, and blood pressure variability or independent DBP effects were not examined.",
          "pmid": "23780706",
          "title": "Green and black tea for the primary prevention of cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract directly analyzes whether low diastolic blood pressure (DBP) is independently associated with worse cardiovascular outcomes, beyond the effect of intensive systolic BP treatment. It reports that low DBP (<60 mmHg) is associated with higher cardiovascular risk (HR 1.90) after adjusting for treatment, indicating an independent relationship between DBP level and outcomes. This aligns with the proposed mechanism that DBP levels influence cardiovascular outcomes independently. While the mediation analysis shows that the pathway from intensive treatment through low DBP is largely confounded, the core mechanistic element\u2014DBP level independently affecting outcomes\u2014is supported.",
          "key_findings": "In SPRINT data (n=9361), low DBP (<60 mmHg) was associated with poor cardiovascular outcomes with HR 1.90 (95% CI 1.46\u20132.47) after adjustment for treatment, indicating an adverse independent association of low DBP with outcomes. Mediation analysis found that the indirect effect of intensive SBP treatment via low DBP attenuated from HR 1.12 (95% CI 1.06\u20131.18) unadjusted to HR 1.04 (95% CI 0.98\u20131.10) after adjustment for covariates, suggesting confounding in the treatment\u2192low DBP\u2192outcome pathway, but not negating the independent association of DBP with outcomes.",
          "pmid": "28841431",
          "title": "Diastolic hypotension due to intensive blood pressure therapy: Is it harmful?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines orthostatic hypotension\u2014defined by acute drops in SBP and/or DBP after standing\u2014and its association with cardiovascular events and mortality. The proposed mechanism concerns DBP levels and variability per se as independent statistical determinants of cardiovascular outcomes and mortality. This review does not analyze DBP level or variability independently of orthostatic hypotension, nor does it separate the contribution of DBP from SBP or from the syndrome as a whole, so it does not directly support or contradict the specific mechanism about DBP variability/levels.",
          "key_findings": "Orthostatic hypotension (\u226520 mmHg SBP and/or \u226510 mmHg DBP fall within 3 minutes of standing) is associated with increased overall mortality (pooled HR 1.36 [1.13\u20131.63]) and higher risk for various cardiovascular events in prospective studies. No clear association was found with stroke or falls, and data were insufficient for meta-analysis on those outcomes. The study does not isolate the effect of DBP variability or DBP levels independent of SBP or orthostatic hypotension as a syndrome.",
          "pmid": "24879490",
          "title": "Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses effects of dietary polyphenols on obesity, adipocyte biology, inflammation, energy expenditure, and glucose homeostasis. It does not mention diastolic blood pressure (DBP), blood pressure variability, cardiovascular outcomes, or mortality, nor any statistical analysis of their independent relationships. Therefore it neither supports nor conflicts with the proposed DBP variability mechanism.",
          "key_findings": "Dietary polyphenols such as green tea catechins, resveratrol, and curcumin influence adipocyte viability, differentiation, triglyceride accumulation, lipolysis, fatty acid oxidation, inflammation, and signaling pathways related to adipogenesis and metabolism; animal models show reduced body weight, fat mass, and triglycerides, while human data on anti-obesity effects are limited and inconsistent.",
          "pmid": "24314860",
          "title": "Novel insights of dietary polyphenols and obesity.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The study shows that cardiovascular risk is influenced not only by ambulatory BP level but also by the BP pattern (blunted nocturnal decline) and that non-dippers have higher CVD risk than dippers even when average SBP/DBP levels are within the normotensive range. This demonstrates a blood pressure variability/pattern component (nighttime dipping status) that independently influences cardiovascular outcomes beyond mean BP levels, consistent with the proposed statistical mechanism that BP variability/levels independently affect outcomes. Although it focuses on nocturnal BP decline rather than explicitly isolated DBP variability, it still supports the broader claim of independent effects of BP pattern/variability and level on CVD risk.",
          "key_findings": "1) In a cohort of 3344 individuals followed for a median of 5.6 years, Cox analyses adjusted for confounders showed non-dippers had significantly higher CVD risk than dippers, both in those with normal ambulatory BP (p = .017) and those with elevated ambulatory BP (p < .001). 2) Non-dippers with normal awake and asleep SBP/DBP means (21% of the population) had a hazard ratio for CVD events of 1.61 (95% CI: 1.09\u20132.37), similar to dippers with elevated ambulatory BP (HR 1.54; 95% CI: 1.01\u20132.36; p = .912 between groups). 3) Authors conclude that CVD risk is influenced not only by ambulatory BP elevation but also by blunted nighttime BP decline, even within the normotensive range, indicating that circadian BP pattern independently affects risk beyond BP level.",
          "pmid": "23039824",
          "title": "Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the \"normotensive non-dipper\" paradox.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes genetic associations of GNB3 haplotypes with blood pressure levels and their variation, but does not evaluate whether DBP variability or DBP levels predict cardiovascular outcomes or mortality independently. It addresses genetic determinants of BP traits, not the prognostic/statistical relationship between DBP patterns and cardiovascular endpoints.",
          "key_findings": "A multivariate meta-analysis of six genetic association studies (16,068 participants) found no significant influence of common GNB3 haplotypes on hypertension, overweight/obesity, or variation in systolic and diastolic blood pressures and BMI, even after multiple sensitivity analyses. The study does not examine cardiovascular outcomes or mortality as endpoints.",
          "pmid": "24477587",
          "title": "Multivariate meta-analysis of the association of G-protein beta 3 gene (GNB3) haplotypes with cardiovascular phenotypes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates tai chi as an intervention for primary prevention of CVD and reports its effects on mean diastolic and systolic blood pressure and lipids, but does not analyze DBP variability, nor does it relate DBP levels or variability to cardiovascular events or mortality. Thus it does not address whether DBP variability or levels independently influence cardiovascular outcomes.",
          "key_findings": "Nine trials measured blood pressure and some showed reductions in DBP (about 4\u201312 mmHg) with tai chi, while others showed no clear effect; no cardiovascular mortality, all-cause mortality, or non-fatal cardiovascular events were reported; CVD risk-factor heterogeneity was high and no long-term outcome data were available.",
          "pmid": "24715694",
          "title": "Tai chi for primary prevention of cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns the influence of diastolic blood pressure (DBP) variability and levels on cardiovascular outcomes and mortality, independently. This abstract examines cross-sectional associations of systolic and diastolic blood pressure levels with QTc interval, not with cardiovascular events or mortality, and does not address BP variability. While it shows DBP is independently associated with QTc, this is an intermediate ECG parameter, not the specified clinical outcomes, so it does not directly support or refute the proposed mechanism.",
          "key_findings": "In a cross-sectional study of 10,553 Chinese adults, higher systolic and diastolic blood pressure levels were independently associated with longer QTc interval after adjustment for cardiovascular confounders and left ventricular mass (\u03b2 = 0.12 for SBP, 0.16 for DBP; both P < 0.001). Hypertension was independently associated with prolonged QTc (OR = 1.71; P < 0.001), with similar associations in both sexes. No data on blood pressure variability, cardiovascular outcomes, or mortality were reported.",
          "pmid": "31360702",
          "title": "Independent Influence of Blood Pressure on QTc Interval: Results from a General Chinese Population.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbp",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Lower DBP increases perfusion mismatch risk and end-organ ischemia in susceptible individuals.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"dbp\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"susceptible\" OR \"individuals\" OR \"perfusion\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 3,
      "neutral_count": 15,
      "support_percentage": 10.0,
      "conflict_percentage": 15.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly notes that setting a lower blood pressure target in pregnancy carries a risk of poor placental perfusion, implying that lowering diastolic blood pressure (DBP) too much can compromise organ (placental/fetal) perfusion. This aligns with the proposed mechanism that lower DBP can increase perfusion mismatch and end-organ ischemia in susceptible individuals. However, the statement is conceptual and precautionary rather than backed by specific quantitative outcome data in this abstract, so confidence is medium rather than high.",
          "key_findings": "The authors state that although expanding the definition of hypertension (adding stage 1) would identify more women at risk of preeclampsia, more research is needed before changing the blood pressure goal, because a lower target BP has a risk of poor placental perfusion. This links lower BP (including DBP) with potentially inadequate perfusion of an end organ (the placenta/fetus).",
          "pmid": "32852628",
          "title": "Hypertension During Pregnancy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that aged black garlic reduces diastolic blood pressure and suggests this may be beneficial, but it does not examine perfusion mismatch, end-organ ischemia, or risk in susceptible individuals. There is no assessment of ischemic outcomes, organ perfusion, or harms from lower DBP, so it neither supports nor contradicts the proposed mechanism that lower DBP increases perfusion mismatch and end-organ ischemia.",
          "key_findings": "In a randomized, double-blind, crossover trial of 67 moderately hypercholesterolemic subjects, 6 weeks of aged black garlic extract (1.25 mg SAC/day) reduced diastolic blood pressure by a mean of 5.85 mm Hg versus placebo, particularly in men with baseline DBP > 75 mm Hg. The authors interpret this as contributing to an optimal DBP but report no data on perfusion mismatch, ischemic events, or end-organ damage.",
          "pmid": "35276764",
          "title": "Effects of an Optimized Aged Garlic Extract on Cardiovascular Disease Risk Factors in Moderate Hypercholesterolemic Subjects: A Randomized, Crossover, Double-Blind, Sustainedand Controlled Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The proposed mechanism states that lower diastolic blood pressure increases the risk of perfusion-related end-organ ischemia in susceptible individuals. The abstract explicitly hypothesizes that DBP <70 mmHg may decrease perfusion to the heart and then shows that achieved DBP <60 mmHg (and even 60\u201369 mmHg) is associated with higher all-cause mortality and adverse cardiovascular outcomes, especially in those with pre-existing cardiovascular disease (i.e., susceptible individuals). While it does not directly measure perfusion mismatch or ischemia, the pattern of worse cardiovascular outcomes with low DBP in vulnerable patients is consistent with the proposed mechanism and provides indirect supportive evidence.",
          "key_findings": "1) Mean achieved DBP <60 mmHg associated with increased all-cause mortality (HR 1.48; 95% CI 1.26\u20131.74), particularly in patients with pre-existing cardiovascular disease. 2) DBP <60 mmHg associated with higher risk of major adverse cardiovascular events (HR 1.84; 95% CI 1.28\u20132.65) and myocardial infarction (HR 1.49; 95% CI 1.13\u20131.97). 3) DBP 60\u201369 mmHg also associated with increased all-cause mortality (HR 1.11; 95% CI 1.03\u20131.20). 4) Authors explicitly note that reduction of DBP below 70 mmHg may decrease perfusion to the heart and worsen cardiovascular outcomes.",
          "pmid": "37866417",
          "title": "Association of low diastolic blood pressure with cardiovascular outcomes and all-cause mortality: A meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that lower diastolic blood pressure (DBP) increases the risk of perfusion mismatch and end-organ ischemia in susceptible individuals. This meta-analysis reports that in both older and younger patients, achieving on-treatment DBP <80 mmHg is associated with significant reductions in cardiovascular outcomes, with no signal of excess adverse events such as hypotension/syncope or treatment discontinuation in older adults. This implies net benefit\u2014not detectable harm\u2014at lower DBP levels, which is inconsistent with the mechanism as a generalizable effect, though the abstract does not specifically probe ischemia at very low DBP or in narrowly defined susceptible subgroups.",
          "key_findings": "1) In patients both older and younger than 65 years, significant reductions in cardiovascular outcomes were observed at on-treatment DBP <80 mmHg.\n2) There was no evidence that treatment discontinuations for adverse events or hypotension/syncope were more frequent in patients >65 years despite BP lowering.\n3) The authors conclude that SBP and DBP values lower than 140 and 80 mmHg, respectively, can be targeted with incremental benefits and without disproportionate burdens up to age 80 years.",
          "pmid": "29847485",
          "title": "Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that lower diastolic blood pressure (DBP) increases perfusion mismatch risk and end-organ (including brain) ischemia in susceptible individuals. In contrast, this meta-analysis reports that higher DBP (\u2265100 mmHg) is associated with an increased risk of post-stroke cognitive impairment, while DBP \u226499 mmHg does not significantly predict PSCI. Thus, the abstract links elevated, not reduced, DBP with worse cognitive outcomes after stroke, which runs counter to the specific low-DBP ischemia mechanism.",
          "key_findings": "In subgroup analysis, DBP \u2265100 mmHg strongly predicted PSCI (OR 1.96, p < 0.00001), whereas DBP \u226499 mmHg showed no significant predictive effect (p > 0.05). The authors conclude that hypertension and higher systolic or diastolic BP are associated with PSCI.",
          "pmid": "39076476",
          "title": "Association between Blood Pressure and Post-Stroke Cognitive Impairment: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that intensive periodontal therapy reduces systolic and diastolic blood pressure, particularly in prehypertensive/hypertensive patients, and improves endothelial function and inflammatory markers. However, it does not examine perfusion mismatch, end-organ ischemia, or risks associated with lower diastolic blood pressure. Thus it neither supports nor contradicts the specific mechanism that lower DBP increases perfusion mismatch and ischemia risk in susceptible individuals.",
          "key_findings": "Intensive periodontal treatment vs conventional treatment led to pooled reductions in DBP (~3 mmHg overall; ~8.4 mmHg in prehypertensive/hypertensive subgroups) and SBP, with improved endothelial function and reduced CRP. No outcomes related to perfusion mismatch or end-organ ischemia were reported.",
          "pmid": "33617973",
          "title": "Periodontal therapy and treatment of hypertension-alternative to the pharmacological approach. A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that lower ambient temperature increases both systolic and diastolic blood pressure, especially in people with cardiovascular conditions. The proposed mechanism concerns how lower DBP might increase perfusion mismatch and end-organ ischemia, but this study does not examine perfusion mismatch, end-organ ischemia, or harms specifically attributable to lower DBP; in fact, DBP rises rather than falls as temperature decreases. Thus the findings are related to blood pressure and susceptibility but do not address the specific mechanism of lower DBP causing perfusion mismatch.",
          "key_findings": "A 1\u00b0C decrease in mean daily outdoor temperature is associated with an increase in SBP of 0.26 mmHg and DBP of 0.13 mmHg; effects are stronger in individuals with cardiovascular-related conditions. Lower indoor temperature is also associated with increased SBP. No outcomes on perfusion mismatch or end-organ ischemia are reported.",
          "pmid": "27750133",
          "title": "Environmental ambient temperature and blood pressure in adults: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how high birth weight relates to systolic/diastolic blood pressure levels and hypertension risk across the life course, but it does not analyze low diastolic blood pressure, perfusion mismatch, or end-organ ischemia. Although DBP is an outcome, there is no discussion of mechanisms linking lower DBP to ischemia or perfusion mismatch, nor stratification by susceptible individuals. Therefore it neither supports nor contradicts the proposed mechanistic claim.",
          "key_findings": "High birth weight is associated with higher SBP, DBP, and hypertension prevalence in childhood, but with lower SBP, DBP, and lower hypertension risk in older adults compared with normal birth weight. A \u2018catch-down\u2019 effect in blood pressure is observed as individuals with high birth weight age.",
          "pmid": "23595042",
          "title": "The associations of high birth weight with blood pressure and hypertension in later life: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that various behavioral interventions (exercise, DASH diet, weight loss) lower diastolic blood pressure, but it does not examine perfusion mismatch, end-organ ischemia, or any harms from lower DBP. Instead, it focuses on cardiovascular structural and vascular benefits. Therefore it neither supports nor contradicts the specific mechanism that lower DBP increases perfusion mismatch and ischemia risk in susceptible individuals.",
          "key_findings": "Exercise, DASH diet, and weight loss each reduce systolic and diastolic blood pressure by several mm Hg; combined exercise and weight loss reduce SBP and DBP by 12.5 and 7.9 mm Hg. These BP reductions are associated with improvements in left ventricular structure and function, reduced arterial stiffness, and improved endothelial function. No data are presented on perfusion mismatch, end-organ ischemia, or adverse outcomes specifically related to lower DBP.",
          "pmid": "15107009",
          "title": "Effects of exercise, diet and weight loss on high blood pressure.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism centers on lower diastolic blood pressure (DBP) increasing perfusion mismatch and ischemia risk, whereas this meta-analysis reports that women with PCOS and sleep disturbance have significantly higher DBP (along with higher SBP and other cardiometabolic risk factors) compared with PCOS women without sleep disturbance. Although the study is not designed to test perfusion mismatch or ischemia directly, the direction of association for DBP (higher, not lower) in a higher\u2011risk group is opposite to what the mechanism emphasizes, providing indirect conflicting evidence regarding the notion that lower DBP is the relevant risk pattern in these susceptible individuals.",
          "key_findings": "In women with PCOS, those with sleep disturbance had significantly higher diastolic blood pressure (DBP), higher systolic blood pressure (SBP), higher BMI, LDL-c, fasting and 2-h glucose, and waist circumference, and lower HDL-c compared with those without sleep disturbance.",
          "pmid": "36176474",
          "title": "Sleep disturbances, sleep quality, and cardiovascular risk factors in women with polycystic ovary syndrome: Systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of portable air cleaners on systolic and diastolic blood pressure, showing modest BP reductions. It does not examine perfusion mismatch, end-organ ischemia, or any differential risk in susceptible individuals at lower DBP levels, nor does it discuss harms from DBP lowering. Thus it neither supports nor contradicts the specific mechanism about lower DBP increasing perfusion mismatch and ischemia risk.",
          "key_findings": "Meta-analysis of 17 studies (~880 participants) found that active portable air cleaner use vs sham reduced SBP by about 2.35\u20133.62 mmHg and DBP by about 0.81\u20131.35 mmHg, with stronger effects after excluding high-bias studies. The work focuses on BP changes as a beneficial mechanism linking reduced PM2.5 exposure to lower cardiovascular risk, without assessing perfusion mismatch or end-organ ischemia at lower DBP.",
          "pmid": "37421892",
          "title": "An updated systematic review and meta-analysis on portable air cleaners and blood pressure: Recommendations for users and manufacturers.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that CPAP treatment in obstructive sleep apnea leads to small reductions in systolic and diastolic blood pressure, including DBP, but it does not assess perfusion mismatch, end-organ ischemia, or outcomes in susceptible individuals. It only quantifies BP changes and does not examine whether lower DBP increases ischemic risk, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 16 RCTs with 1166 patients, CPAP reduced office SBP by about 3.2 mmHg and office DBP by about 2.9 mmHg; reduced night-time SBP and mean 24-h and night-time blood pressure, including 24-h DBP by about 3.5 mmHg. No significant change was observed in daytime SBP or DBP. No data on perfusion mismatch or end-organ ischemia were reported.",
          "pmid": "24979300",
          "title": "Continuous positive airway pressure reduces blood pressure in patients with obstructive sleep apnea; a systematic review and meta-analysis with 1000 patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links higher sodium intake to higher systolic and diastolic blood pressure at individual and population levels but does not examine diastolic blood pressure lowering, perfusion mismatch, or end-organ ischemia. It addresses determinants of blood pressure, not consequences of lower DBP or ischemic outcomes in susceptible individuals.",
          "key_findings": "A 100 mmol/day higher sodium intake is associated with approximately 3\u20136 mm Hg higher SBP and 0\u20133 mm Hg higher DBP in individuals, and with higher median SBP/DBP, hypertension prevalence, and steeper age-related SBP/DBP slopes across populations. The study concludes that high salt intake is an important preventable cause of adverse population-wide blood pressure patterns and cardiovascular risk, but does not analyze risks arising from low DBP or perfusion mismatch.",
          "pmid": "9022559",
          "title": "The INTERSALT Study: background, methods, findings, and implications.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that walnut consumption did not change systolic or diastolic blood pressure in metabolic syndrome patients, but it does not examine perfusion mismatch, end-organ ischemia, or differential risk in susceptible individuals. Thus it neither supports nor contradicts the proposed mechanism about lower DBP leading to perfusion mismatch and ischemia.",
          "key_findings": "In a meta-analysis of 8 RCTs in 549 adults with metabolic syndrome, walnut consumption significantly reduced triglycerides but did not affect other lipid parameters, glucose homeostasis markers, hs-CRP, anthropometric indices, or blood pressure (SBP and DBP).",
          "pmid": "35338001",
          "title": "Impact of walnut consumption on cardio metabolic and anthropometric parameters in metabolic syndrome patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports a GWAS/meta-analysis identifying genetic variants associated with systolic and diastolic blood pressure in individuals of African ancestry. It does not examine how lower diastolic blood pressure affects perfusion mismatch or end-organ ischemia, nor does it assess clinical outcomes related to ischemia or perfusion. Thus, it neither supports nor contradicts the proposed mechanistic link between lower DBP and perfusion-related ischemic risk.",
          "key_findings": "Identification of multiple genetic variants associated with SBP and DBP in 80,950 individuals of African ancestry, including one novel variant (rs562545 in MOBP). The study focuses on genetic architecture and biological processes linked to blood pressure traits, without analyzing perfusion mismatch, end-organ ischemia, or outcome risks associated with low DBP.",
          "pmid": "36768488",
          "title": "Meta-Analysis and Multivariate GWAS Analyses in 80,950 Individuals of African Ancestry Identify Novel Variants Associated with Blood Pressure Traits.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract defines orthostatic hypotension as a fall in systolic or diastolic blood pressure and links it to presyncope/syncope due to autonomic failure, but it does not specifically discuss perfusion mismatch, end-organ ischemia, or differential vulnerability of susceptible individuals related to lower diastolic blood pressure. Thus, it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "Orthostatic hypotension is defined as a reduction of systolic BP \u226520 mm Hg or diastolic BP \u226510 mm Hg within 3 minutes of standing. The fall in blood pressure results from autonomic nervous system failure to maintain adequate venous return and vasoconstriction, leading to presyncopal states or syncope. The abstract focuses on pathophysiology, diagnosis, and treatment (e.g., fludrocortisone, midodrine, SSRIs) and mentions increased risk in the elderly, but does not address perfusion mismatch or end-organ ischemia at low diastolic blood pressure.",
          "pmid": "18091397",
          "title": "Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the shift from diastolic to systolic blood pressure as the primary predictor and treatment target for cardiovascular risk, but it does not examine the consequences of lower DBP, perfusion mismatch, or end-organ ischemia. There is no analysis of low DBP levels, J-curve phenomena, or ischemic outcomes specifically linked to reduced diastolic pressure.",
          "key_findings": "Systolic blood pressure is shown to be a better predictor than diastolic blood pressure for strokes and coronary heart disease; trials of isolated systolic hypertension demonstrate that lowering SBP reduces stroke, heart failure, CHD, and all-cause mortality; treatment guidelines and meta-analyses emphasize focusing on lowering SBP, but the impact of lowering DBP itself or any associated perfusion/ischemia risk is not addressed.",
          "pmid": "15592571",
          "title": "The paradigm has shifted to systolic blood pressure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that Nigella sativa modestly lowers both systolic and diastolic blood pressure, including an average DBP reduction of about 2.8 mmHg. However, it does not examine perfusion mismatch, end-organ ischemia, susceptible subpopulations, or any adverse ischemic outcomes related to lower DBP. Thus it neither supports nor contradicts the proposed mechanism that lower DBP increases perfusion mismatch\u2013related ischemia.",
          "key_findings": "Meta-analysis of 11 RCTs (860 participants) found that Nigella sativa supplementation reduced DBP by \u22122.80 mmHg and SBP by \u22123.26 mmHg compared with controls over a mean of 8.3 weeks. No data on perfusion mismatch, tissue ischemia, or ischemic clinical events were reported.",
          "pmid": "27512971",
          "title": "A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses renalase, catecholamines, and their effects on systolic and diastolic blood pressure, hypertension, and cardiac ischemia risk, but it does not address how lower diastolic blood pressure might increase perfusion mismatch or end-organ ischemia. Where ischemia is mentioned, it is linked to a renalase mutation in people with comparable blood pressure, not to reduced DBP or perfusion changes. Thus it neither supports nor contradicts the proposed mechanism about low DBP causing perfusion mismatch\u2013related ischemia.",
          "key_findings": "1) Renalase deficiency is associated with increased SBP and DBP and elevated circulating catecholamines in animal models.\n2) Recombinant renalase has a potent antihypertensive effect in Dahl salt-sensitive rats and rats with chronic kidney disease.\n3) Plasma renalase levels are inversely associated with SBP in patients with resistant hypertension.\n4) A functional renalase mutation (Glu37Asp) is associated with essential hypertension and predicts more severe cardiac hypertrophy, dysfunction, and ischemia in individuals with stable coronary artery disease, despite comparable blood pressure and normal renal function.\n5) Renal and cardiac functions are reportedly unaffected in renalase knockout mice, despite increased SBP and DBP and evidence of sympathetic activation.",
          "pmid": "21099685",
          "title": "Role of renalase in the regulation of blood pressure and the renal dopamine system.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that resistance training slightly lowers resting DBP and can cause post-exercise hypotension, but it does not examine perfusion mismatch, end-organ ischemia, or susceptibility factors. There is no direct evidence linking lower DBP to increased risk of perfusion-related ischemia in this text.",
          "key_findings": "Chronic resistance training slightly reduces resting SBP and DBP; single sessions can produce post-exercise hypotension in normal and hypertensive individuals; cardiovascular stability is observed during resistance exercise in coronary disease or heart failure patients, with no apparent detriment to ventricular function.",
          "pmid": "17992383",
          "title": "Hemodynamic and vascular effects of resistance training: implications for cardiovascular disease.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "screat",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Higher serum creatinine indicates reduced nephron mass and renal function impacting cardiovascular health.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"screat\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"cardiovascular\" OR \"creatinine\" OR \"impacting\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "screat",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Impaired renal function alters pharmacokinetics, increasing sensitivity or reducing antihypertensive efficacy.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"screat\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"antihypertensive\" OR \"pharmacokinetics\" OR \"sensitivity\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "screat",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "High serum creatinine co-occurs with other cardiovascular risks, compounding them.",
        "evidence_level": "moderate"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"screat\" AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"cardiovascular\" OR \"compounding\" OR \"creatinine\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "chr",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Cholesterol promotes atherosclerosis, affecting cardiovascular risk and BP control benefits.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"chr\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"atherosclerosis\" OR \"cardiovascular\" OR \"cholesterol\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 10.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The mechanism claims that cholesterol promotes atherosclerosis and thereby influences cardiovascular risk. The abstract reports that reduced free testosterone is associated with a pro\u2011atherogenic lipid profile characterized by decreased HDL\u2011cholesterol and increased triglycerides, which is clinically relevant for coronary artery disease. This supports the notion that adverse cholesterol/lipid profiles promote atherosclerotic cardiovascular disease, though it does not address blood pressure control benefits or cholesterol causality in detail.",
          "key_findings": "Reduced free testosterone serum levels, whether age-related or in premature coronary artery disease patients, are said to promote a pro\u2011atherogenic lipid profile, specifically decreased HDL-cholesterol and increased triglycerides, which has relevant clinical significance for the evaluation and treatment of coronary artery disease.",
          "pmid": "15493157",
          "title": "[Heart and androgens].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the relationship between ambulatory hypertension and target organ damage (LVH, arterial stiffness, carotid intima-media thickness) in children, and the effect of BMI on these outcomes. It does not measure cholesterol, lipid levels, or their role in atherosclerosis or BP control benefits, so it neither supports nor contradicts the proposed mechanism about cholesterol promoting atherosclerosis and affecting cardiovascular risk and BP control.",
          "key_findings": "Children with ambulatory hypertension (vs. normotensive peers) had higher risk of LVH (OR 4.69), greater left ventricular mass index, higher pulse wave velocity, and greater carotid intima-media thickness. BMI positively influenced left ventricular mass index and carotid intima-media thickness. No cholesterol or lipid parameters were reported.",
          "pmid": "36802759",
          "title": "Risk of Target Organ Damage in Children With Primary Ambulatory Hypertension: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses chrysophanol\u2019s general anti-cardiovascular disease activity via modulation of signaling pathways and its pharmacokinetics, but it does not mention cholesterol, atherosclerosis, lipid metabolism, cardiovascular risk linked to cholesterol, or blood pressure control. Therefore it neither supports nor contradicts the specific mechanism that cholesterol promotes atherosclerosis and affects cardiovascular risk and BP control benefits.",
          "key_findings": "Chrysophanol from Rheum species has anti-inflammatory, anti-cancer, neuroprotective, and anti-cardiovascular disease activities, primarily via regulation of signaling pathways such as NF-\u03baB, MAPK, and PI3K/Akt; modified formulations (nanoparticles, liposomes) improve its bioavailability. No data are provided on cholesterol, atherosclerosis, or blood pressure.",
          "pmid": "32066044",
          "title": "The pharmacological properties of chrysophanol, the recent advances.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates mortality and survival effects of erythropoiesis-stimulating agents in cancer patients and reports thromboembolic/cardiovascular outcomes only as part of the stated objectives, without presenting any data on cholesterol levels, atherosclerosis, or blood pressure control. It does not investigate cholesterol-mediated mechanisms or cardiovascular risk pathways relevant to the proposed mechanism.",
          "key_findings": "In a meta-analysis of 53 trials including 13,933 cancer patients, erythropoiesis-stimulating agents increased on-study mortality (HR 1.17, 95% CI 1.06\u20131.30) and worsened overall survival (HR 1.06, 95% CI 1.00\u20131.12). The abstract does not report on cholesterol, atherosclerotic outcomes, or blood pressure effects.",
          "pmid": "19588423",
          "title": "Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on chromogranin A and its peptides in immunity, inflammation, autoimmunity, and infections. It does not discuss cholesterol, lipid metabolism, atherosclerosis, cardiovascular risk modification by cholesterol, or blood pressure control benefits. Therefore it neither supports nor contradicts the proposed cholesterol\u2013atherosclerosis mechanism.",
          "key_findings": "Chromogranin A is described as a prohormone for various bioactive peptides (e.g., catestatin, vasostatins, pancreastatin) that have complex and sometimes opposing roles in inflammation, macrophage polarization (M1 vs M2), Th1 responses, antimicrobial activity, and autoimmunity. Its roles in cardiovascular and other immune-mediated diseases are mentioned in general but without reference to cholesterol or atherosclerotic mechanisms.",
          "pmid": "40370467",
          "title": "A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses genetic determinants of stress responses and their relationship to cardiovascular disease and hypertension, focusing on stress pathways, temperature response, and specific QTLs. It does not mention cholesterol, lipids, atherosclerosis, or how cholesterol might influence cardiovascular risk or blood pressure control benefits.",
          "key_findings": "The study links variability in stress responses (e.g., increased body temperature) to specific genetic loci (myh3 on Chr 10, hsp27 on Chr 12, a locus on Chr Y, and hstf1 on Chr 7) in rats and discusses enhanced stress responsiveness as a trait in cardiovascular disease and hypertension. No data on cholesterol, atherosclerosis, or lipid-mediated cardiovascular risk are provided.",
          "pmid": "12040536",
          "title": "Genetic determinants of the stress response in cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses procedural outcomes and clinical benefits of PCI for chronic total occlusions but does not mention cholesterol levels, lipid biology, atherosclerosis development, or how cholesterol affects cardiovascular risk or blood pressure control. Therefore, it neither supports nor conflicts with the proposed cholesterol-related mechanism.",
          "key_findings": "Successful CTO-PCI is associated with improved cardiovascular outcomes and quality of life, interest in CTO-PCI has grown due to better equipment and techniques, and patient selection factors include symptoms, ischemia extent, and myocardial viability; no data on cholesterol or its role in atherosclerosis are presented.",
          "pmid": "28705045",
          "title": "Percutaneous coronary interventions of chronic total -occlusions; a review of clinical indications, treatment strategy and current practice.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract states that raised cholesterol concentrations are associated with heightened risk for coronary heart disease, and discusses cholesterol as a key factor in atherothrombotic disease, which aligns with the mechanism that cholesterol promotes atherosclerosis and thereby influences cardiovascular risk. While it does not explicitly discuss blood pressure control benefits, it clearly supports the core link between elevated cholesterol and atherosclerotic cardiovascular risk.",
          "key_findings": "1) Anatomopathological, biological and epidemiological studies suggest that raised cholesterol concentrations are associated with heightened risk for coronary heart disease. 2) Consensus conferences recommend preventive measures (diet and cholesterol-lowering drugs) to achieve desirable plasma cholesterol levels. 3) The abstract emphasizes continued detection and treatment of familial hypercholesterolemia and recognizes cholesterol-related atherothrombotic risk, while also noting interest in additional factors (HDL, triglycerides, hypercoagulability).",
          "pmid": "7944281",
          "title": "[Cholesterol: consensus and controversies, what is the trend in 1993?].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract investigates effects of magnesium supplementation on resistance exercise performance, blood pressure, and total peripheral resistance in normotensive adults. It does not measure cholesterol, lipid profiles, atherosclerosis, or cardiovascular events, nor does it discuss cholesterol-mediated mechanisms of blood pressure control or cardiovascular risk. Therefore, it neither supports nor contradicts the proposed mechanism involving cholesterol and atherosclerosis.",
          "key_findings": "In a randomized, double-blind, placebo-controlled cross-over study (n=13), acute (1-week) vs chronic (4-week) oral magnesium supplementation (300 mg/day) was compared. Acute loading increased bench press performance by 7.7% and maintained performance on day 2, while chronic loading led to a 32.1% decrease on day 2. On day 2, post-exercise systolic blood pressure was significantly lower in both acute and chronic groups; diastolic blood pressure decreased significantly only in the acute group. Total peripheral resistance decreased with acute loading on both days, but increased on day 1 with chronic loading. No cumulative benefit of chronic over acute supplementation was found. No data or discussion related to cholesterol or atherosclerosis were provided.",
          "pmid": "25945079",
          "title": "The effect of acute vs chronic magnesium supplementation on exercise and recovery on resistance exercise, blood pressure and total peripheral resistance on normotensive adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on osteoporosis risk and fracture prevention in prostate cancer patients receiving androgen-deprivation therapy. It does not mention cholesterol levels, atherosclerosis, cardiovascular risk, or blood pressure control, nor any mechanistic links between these and treatment outcomes.",
          "key_findings": "ADT for prostate cancer causes rapid bone loss and increases fracture risk; French societies propose criteria for osteoporosis assessment and treatment (based on T-score, fracture history, age, BMI, comorbidities, glucocorticoid use, falls). Cardiovascular or cholesterol-related mechanisms are not addressed.",
          "pmid": "30287350",
          "title": "French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses Swan-Ganz catheter\u2013induced pulmonary artery perforation as a surgical/iatrogenic complication during cardiac surgery. It does not mention cholesterol, atherosclerosis, cardiovascular risk modulation by cholesterol, or blood pressure control, and provides no mechanistic or associative data regarding cholesterol\u2019s role in atherosclerosis or cardiovascular outcomes.",
          "key_findings": "Reports two cases of pulmonary artery perforation from Swan-Ganz catheters during cardiac surgery requiring immediate hemostasis lobectomy; identifies risk factors such as age >60, pulmonary hypertension, anticoagulant therapy, hypothermia, and cardiac manipulation; notes high potential mortality and recommends early diagnosis and surgical treatment.",
          "pmid": "8698771",
          "title": "Swan-Ganz catheter induced pulmonary artery perforation during cardiac surgery concerning two cases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract investigates effects of high-intensity exercise on fitness, symptoms, cognition, and hippocampal structure/connectivity in individuals at clinical high risk for psychosis. It does not measure cholesterol, atherosclerosis, cardiovascular risk, or blood pressure, nor does it discuss cholesterol-mediated mechanisms. Therefore it neither supports nor contradicts the proposed mechanism about cholesterol promoting atherosclerosis and affecting cardiovascular risk and BP control benefits.",
          "key_findings": "High-intensity interval exercise in CHR-p individuals improved fitness, cognitive performance, and positive symptoms; preserved hippocampal volumes (vs. 3.57% decrease in hippocampal subfield volume in waitlist); and increased hippocampal connectivity. No data on cholesterol, atherosclerosis, cardiovascular risk, or blood pressure are reported.",
          "pmid": "35810336",
          "title": "Exercise Intervention in Individuals at Clinical High Risk for Psychosis: Benefits to Fitness, Symptoms, Hippocampal Volumes, and Functional Connectivity.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses trimetazidine\u2019s effects on cardiac energy metabolism in heart failure, focusing on fatty acid and glucose oxidation and clinical benefits without hemodynamic effects. It does not mention cholesterol, atherosclerosis, cardiovascular risk modification via lipid pathways, or blood pressure control, so it neither supports nor contradicts the proposed cholesterol-related mechanism.",
          "key_findings": "Trimetazidine modulates cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation, improving symptoms, cardiac function, and prognosis in heart failure patients without negative hemodynamic effects; no data on cholesterol, atherosclerosis, or BP-related risk modification are provided.",
          "pmid": "26618252",
          "title": "Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study examines effects of arteriovenous fistula ligation on cardiac structure and function and blood pressure in kidney transplant recipients. It does not measure cholesterol, lipid levels, atherosclerosis progression, or link cholesterol to cardiovascular remodeling or BP control. Therefore it neither supports nor contradicts the proposed mechanism about cholesterol-driven atherosclerosis affecting cardiovascular risk and BP benefits.",
          "key_findings": "AVF ligation in stable kidney transplant recipients led to a significant reduction in left ventricular mass and decreases in LV volumes, atrial volumes, cardiac output/index, and NT-proBNP, without significant changes in ejection fraction, pulmonary artery velocity, estimated GFR, or systolic/diastolic blood pressure. No data on cholesterol or atherosclerosis were reported.",
          "pmid": "31045455",
          "title": "Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on dornase alfa, NETs, and ARDS outcomes in COVID-19 and does not address cholesterol, atherosclerosis, cardiovascular risk, or blood pressure control. Therefore it neither supports nor contradicts the proposed cholesterol-related mechanism.",
          "key_findings": "Aerosolized dornase alfa in intubated COVID-19 ARDS patients did not significantly improve ARDS severity at Day 7 or secondary clinical outcomes versus standard of care, and showed bioavailability limitations and similar safety to control. No measurements or discussion of cholesterol, atherosclerosis, cardiovascular events, or blood pressure are included.",
          "pmid": "41125713",
          "title": "Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses a randomized controlled trial of vitamin D supplementation and melanoma relapse-free survival. It does not mention cholesterol, atherosclerosis, cardiovascular risk, or blood pressure control, nor any pathway linking cholesterol to disease outcomes. Therefore, it provides no evidence for or against the proposed cholesterol\u2013atherosclerosis mechanism.",
          "key_findings": "The trial evaluates whether monthly high\u2011dose cholecalciferol after surgical resection of stage IB\u2013III cutaneous malignant melanoma improves relapse-free survival and how this relates to serum vitamin D levels and vitamin D receptor expression; no data or discussion on cholesterol, cardiovascular disease, or blood pressure is included.",
          "pmid": "28835228",
          "title": "Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates reduced-dose rivaroxaban versus dual antiplatelet therapy after left atrial appendage closure, focusing on thrombin generation, coagulation biomarkers, and device thrombosis. It does not measure cholesterol levels, atherosclerotic progression, cardiovascular risk modulation by cholesterol, or blood pressure control, nor does it discuss cholesterol-related mechanisms.",
          "key_findings": "Reduced-dose rivaroxaban (10 mg and 15 mg) lowers thrombin generation and coagulation markers more than dual antiplatelet therapy after left atrial appendage closure, with similar clinical outcomes over 3 months and two device thromboses occurring in the DAPT group. No data on cholesterol, atherosclerosis progression, or BP-related benefits are presented.",
          "pmid": "32674675",
          "title": "Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares bag-mask ventilation vs endotracheal intubation during cardiopulmonary resuscitation and reports neurological and survival outcomes, along with airway management complications. It does not mention cholesterol, atherosclerosis, cardiovascular risk modification, or blood pressure control, and thus provides no evidence for or against the proposed cholesterol-related mechanism.",
          "key_findings": "Bag-mask ventilation and endotracheal intubation showed similar rates of favorable neurological outcome and survival at 28 days after out-of-hospital cardiorespiratory arrest, with differing complication profiles (more difficult airway management, failure, and regurgitation with bag-mask ventilation), but no data related to cholesterol or atherosclerosis.",
          "pmid": "29486039",
          "title": "Effect of Bag-Mask Ventilation vs Endotracheal Intubation During Cardiopulmonary Resuscitation on Neurological Outcome After Out-of-Hospital Cardiorespiratory Arrest: A Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns cardiovascular and pulmonary consequences of severe subarachnoid hemorrhage and does not mention cholesterol, atherosclerosis, long-term cardiovascular risk modification, or blood pressure control benefits. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The abstract (title only) suggests discussion of acute cardiovascular and pulmonary effects following severe subarachnoid hemorrhage; no data or statements regarding cholesterol levels, atherosclerotic processes, or their impact on cardiovascular risk or BP control are provided.",
          "pmid": "15885973",
          "title": "[Cardiovascular and pulmonary consequences of severe subarachnoid haemorrhage].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates heptaminol\u2019s effect on orthostatic hypotension and blood pressure in Parkinsonian patients, with some commentary on sympathetic tone and renin activity. It does not measure cholesterol, atherosclerosis, cardiovascular risk, or how cholesterol modulates BP control benefits, nor does it discuss lipid-related mechanisms. Therefore it neither supports nor contradicts the proposed cholesterol\u2013atherosclerosis mechanism.",
          "key_findings": "Injectable heptaminol (626 mg) significantly increased systolic blood pressure 15 minutes after administration in Parkinsonian patients with spontaneous or bromocriptine-induced orthostatic hypotension; clinical and biological tolerance was excellent; low plasma renin activity and absent orthostatic renin response suggested loss of sympathetic tone; the anti-hypotensive effect did not appear related to renal or sympathetic interactions.",
          "pmid": "2096108",
          "title": "Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "chr",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Cholesterol influences antihypertensive drug effects through lipid metabolism and plaque stability.",
        "evidence_level": "moderate"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"chr\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"antihypertensive\" OR \"cholesterol\" OR \"metabolism\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 2,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 2,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses trimetazidine\u2019s benefits in heart failure via modulation of cardiac energy metabolism (fatty acid vs glucose oxidation). It does not mention cholesterol levels, lipid metabolism in the sense of systemic cholesterol handling, atherosclerotic plaque stability, or interactions with antihypertensive drugs. Therefore, it neither supports nor contradicts the proposed mechanism about cholesterol influencing antihypertensive drug effects through lipid metabolism and plaque stability.",
          "key_findings": "Trimetazidine, when added to conventional medical therapy in heart failure, improves symptoms, cardiac function, and prognosis by acting on cardiac metabolism (reducing fatty acid oxidation and/or increasing glucose oxidation) without negative hemodynamic effects.",
          "pmid": "26618252",
          "title": "Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract investigates aerosolized dornase alfa in COVID-19 ARDS via NET degradation and DNAse activity; it does not involve cholesterol, lipid metabolism, plaque stability, or antihypertensive drug effects, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Aerosolized dornase alfa did not significantly improve ARDS severity, mortality, or ventilator/ICU-free days compared to standard of care, and showed no significant impact on NET-related markers or DNAse activity due to likely bioavailability issues; safety profiles were similar between groups.",
          "pmid": "41125713",
          "title": "Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "chr",
      "mechanism": {
        "mechanism_type": "behavioral",
        "description": "Cholesterol management through lifestyle can alter blood pressure independent of drugs.",
        "evidence_level": "strong"
      },
      "query": "(hypertension OR \"blood pressure\" OR cardiovascular OR \"intensive treatment\") AND \"chr\" AND (\"cholesterol\" OR \"independent\" OR \"management\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 19,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of oral semaglutide (a drug) plus lifestyle intervention on body weight and safety in adults with overweight/obesity. It does not report on cholesterol management, blood pressure outcomes, or whether lifestyle-based cholesterol changes independently alter blood pressure in the absence of drugs. Any lifestyle component is co-administered with a pharmacologic agent, so the mechanism of interest (behavioral cholesterol management affecting blood pressure independent of drugs) is not addressed.",
          "key_findings": "Oral semaglutide 50 mg once daily plus lifestyle intervention produced a significantly greater mean body weight reduction (\u221215.1% vs \u22122.4% with placebo) and higher proportions achieving \u22655%, 10%, 15%, and 20% weight loss compared with placebo, with more frequent gastrointestinal adverse events. No outcomes on cholesterol or blood pressure are reported.",
          "pmid": "37385278",
          "title": "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on preeclampsia, its complications, and prophylaxis with aspirin, plus long-term cardiovascular risk. It does not discuss cholesterol, lifestyle-based cholesterol management, or any independent effect of such management on blood pressure.",
          "key_findings": "Preeclampsia is a leading cause of maternal and fetal mortality; termination of pregnancy and delivery of the placenta is the only definitive treatment; aspirin 160 mg/day is currently the only efficient prophylaxis in high-risk patients; preeclampsia is a long-term risk factor for cardiovascular, renal, and neurological diseases.",
          "pmid": "38869138",
          "title": "[Prevention of preeclampsia and its complications].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines effects of probiotic supplementation on gestational diabetes, pre-eclampsia, and other pregnancy outcomes. It does not measure cholesterol levels, cholesterol management behaviors, or blood pressure changes as a function of lifestyle-based cholesterol control, nor does it assess drug-independent effects of cholesterol management on blood pressure. Any mention of hypertensive disorders is in relation to probiotics, not lifestyle cholesterol management.",
          "key_findings": "Probiotics did not clearly affect risk of gestational diabetes (RR 0.80, 95% CI 0.54\u20131.20; low-certainty) but increased risk of pre-eclampsia (RR 1.85, 95% CI 1.04\u20133.29; high-certainty). There was little to no difference in caesarean section, maternal weight gain, large-for-gestational age infants, or neonatal adiposity compared with placebo. The study does not report on cholesterol management, lipid levels, or blood pressure changes due to lifestyle.",
          "pmid": "33870484",
          "title": "Probiotics for preventing gestational diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on anticoagulation and thromboprophylaxis strategies in COVID-19 patients, without discussing cholesterol, lifestyle-based cholesterol management, or blood pressure effects. It neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "COVID-19 is linked with increased thrombotic risk; the paper updates Belgian clinical guidance on anticoagulation management and thromboprophylaxis dosing and risk assessment in hospitalized and ambulatory COVID-19 patients. No mention of cholesterol, lifestyle interventions, or blood pressure outcomes.",
          "pmid": "37548503",
          "title": "The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on guideline development for acute management of severe thermal burns, covering assessment, hemodynamics, airway, analgesia, wound care, and other treatments. It does not mention cholesterol, lipid management, lifestyle interventions, or their relationship to blood pressure, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Expert consensus guidelines were developed for acute burn management in adults and children across six domains, based mainly on expert opinion due to limited high-quality outcome data; cholesterol management, lifestyle factors, and blood pressure modulation are not addressed.",
          "pmid": "32147581",
          "title": "Management of severe thermal burns in the acute phase in adults and children.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses effects of androgens on cardiovascular physiology, lipid profiles, inflammation, and vascular resistance, but does not address lifestyle-based cholesterol management, nor its impact on blood pressure independent of drugs. No behavioral or lifestyle interventions are mentioned, and blood pressure outcomes are not directly evaluated.",
          "key_findings": "Reduced free testosterone is associated with a pro-atherogenic lipid profile (decreased HDL and increased triglycerides); androgens influence cardiomyocyte hypertrophy, inflammatory cytokines in heart failure, and coronary vasodilation. These are hormonal and pathophysiological observations, not lifestyle-mediated cholesterol management or its relationship to blood pressure.",
          "pmid": "15493157",
          "title": "[Heart and androgens].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses LDL cholesterol, lipoprotein-associated phospholipase A2 (Lp-PLA2) as a biomarker, and pharmacologic inhibition of Lp-PLA2 in relation to plaque inflammation and cardiovascular risk. It does not address lifestyle-based cholesterol management, blood pressure changes, or any effect of lifestyle on blood pressure independent of drugs. Therefore it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "Lp-PLA2 is described as an inflammatory, vascular-specific biomarker associated with plaque instability, rupture, and increased risk of cardiovascular events and ischemic stroke. A meta-analysis of 20,000 patients links high Lp-PLA2 levels to higher cardiovascular risk. Pharmacologic inhibition of Lp-PLA2 (drapalib) is reported to prevent necrotic core progression and reduce plaque inflammation. The abstract recommends more aggressive treatment for patients at moderate or high CHD risk with elevated Lp-PLA2. No lifestyle or blood pressure outcomes are discussed.",
          "pmid": "22164942",
          "title": "[Lipoprotein associated phospholipase A2].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of erythropoiesis-stimulating agents on mortality and survival in cancer patients. It does not address cholesterol management, lifestyle interventions, or blood pressure outcomes, nor any relationship among these variables. Therefore it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "In a meta-analysis of 53 randomized trials with 13,933 cancer patients, erythropoiesis-stimulating agents (epoetin or darbepoetin) increased on-study mortality (HR 1.17, 95% CI 1.06\u20131.30) and worsened overall survival (HR 1.06, 95% CI 1.00\u20131.12). These effects were similar across subgroups and cancer treatments, including chemotherapy. No data on lifestyle, cholesterol management, or blood pressure were reported.",
          "pmid": "19588423",
          "title": "Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on ICU management and outcomes of critically ill HIV-infected patients in the cART era. It does not mention cholesterol, lifestyle-based cholesterol management, blood pressure, or the independence from drug effects, so it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "The abstract describes changes over 40 years in causes of ICU admission, types of comorbidities, patterns of opportunistic infections, and mortality in HIV-infected patients treated with cART, as well as evolving critical care and ethical management. No data or discussion is provided on lifestyle cholesterol management or its effects on blood pressure.",
          "pmid": "31421114",
          "title": "Critically Ill Patients With HIV: 40 Years Later.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates probiotic supplementation in gestational diabetes and reports minor effects on lipids (including total cholesterol) and uncertainty about effects on hypertensive disorders of pregnancy and other blood pressure\u2013related outcomes. It does not study lifestyle-based cholesterol management, nor does it demonstrate that cholesterol changes from lifestyle interventions alter blood pressure independently of drugs. Any lipid changes from probiotics are not clearly linked to blood pressure changes, so the proposed mechanism is neither supported nor contradicted.",
          "key_findings": "Probiotics in women with gestational diabetes may slightly reduce triglycerides and total cholesterol and improve insulin resistance markers, but low-certainty evidence shows uncertain effects on hypertensive disorders of pregnancy, with risk ratio 1.50 (95% CI 0.64\u20133.53). The review concludes evidence is limited, heterogeneous, and underpowered, with no clear blood pressure outcome changes attributable to the observed lipid changes.",
          "pmid": "32575163",
          "title": "Probiotic treatment for women with gestational diabetes to improve maternal and infant health and well-being.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses non-invasive diagnosis, staging, and monitoring of chronic hepatitis B virus infection, including virological tests, liver fibrosis assessment, and hepatocellular carcinoma screening. It does not mention cholesterol management, lifestyle interventions, blood pressure, or any relationship between cholesterol management and blood pressure.",
          "key_findings": "The paper focuses on HBV diagnosis and follow-up using clinical, biological, and imaging criteria; virological tools (HBV DNA, HBsAg, HBeAg); non-invasive liver fibrosis assessment; and surveillance for hepatocellular carcinoma. No data or claims about cholesterol, lifestyle-based cholesterol management, antihypertensive effects, or blood pressure are presented.",
          "pmid": "34332134",
          "title": "Non-invasive diagnosis and follow-up of chronic infection with hepatitis B virus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses psoriasis as a systemic inflammatory disease with cardiovascular and metabolic comorbidities and notes that adequate systemic treatment may prevent some comorbidities. It does not address cholesterol management through lifestyle, its impact on cholesterol, or any effect on blood pressure independent of drugs. Therefore it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "Psoriasis is linked to cardiovascular and metabolic comorbidities via chronic inflammation and endothelial dysfunction; patient management should be multidisciplinary; preliminary data suggest adequate systemic (pharmacologic) treatment of psoriasis may prevent some comorbidities. No mention of lifestyle-based cholesterol management or its effects on blood pressure.",
          "pmid": "22136910",
          "title": "[Psoriasis: a systemic disease].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses percutaneous coronary intervention for chronic total occlusions, focusing on revascularization techniques, outcomes, and patient selection. It does not address cholesterol management, lifestyle interventions, or their effects on blood pressure, nor drug-independent blood pressure changes.",
          "key_findings": "Successful CTO revascularization via PCI is associated with better cardiovascular outcomes and quality of life, though prognostic benefit is debated due to lack of randomized trials; recent technical advances have improved success and safety of CTO-PCI.",
          "pmid": "28705045",
          "title": "Percutaneous coronary interventions of chronic total -occlusions; a review of clinical indications, treatment strategy and current practice.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports genetic associations (GWAS) and experimental zebrafish data related to kidney function decline and specific loci (UMOD, GALNT11, CDH23). It does not address cholesterol management, lifestyle interventions, blood pressure, or independence from drug effects, so it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "GWAS meta-analysis in 63,558 Europeans identified loci (UMOD, GALNT11, CDH23) associated with annual eGFR decline and rapid kidney function decline; UMOD association was genome-wide significant and replicated. Zebrafish knockdowns of galnt11 and cdh23 showed severe edema after gentamicin without prior gross renal abnormalities, suggesting roles for GALNT11 and CDH23 in kidney function deterioration.",
          "pmid": "25493955",
          "title": "Genome-wide association study of kidney function decline in individuals of European descent.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates a trauma coagulopathy clinical score (TICCS) for early identification of patients needing damage control resuscitation. It does not address cholesterol management, lifestyle interventions, chronic blood pressure regulation, or any relationship between cholesterol and blood pressure independent of drugs.",
          "key_findings": "TICCS, a prehospital clinical score based on general severity, blood pressure, and extent of injury, showed high discriminatory ability (AUC 0.98) to identify trauma patients needing damage control resuscitation, with a cutoff of 10 yielding 100% sensitivity and 95.9% specificity. The study focuses on acute trauma care and coagulopathy, not on lifestyle-based cholesterol management or its effects on blood pressure.",
          "pmid": "25425230",
          "title": "Prehospital identification of trauma patients with early acute coagulopathy and massive bleeding: results of a prospective non-interventional clinical trial evaluating the Trauma Induced Coagulopathy Clinical Score (TICCS).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses guidelines for diagnosis and management of idiopathic pulmonary fibrosis, including antifibrotic therapy, lung transplantation, symptom management, and comorbidities, but does not mention cholesterol, lipid management, lifestyle interventions, or blood pressure. Therefore, it neither supports nor contradicts the proposed mechanism about cholesterol management through lifestyle altering blood pressure.",
          "key_findings": "The guidelines address epidemiology, diagnostic modalities (including CT and biopsy), genetic testing, antifibrotic therapy, lung transplantation, management of symptoms, comorbidities, complications, chronic respiratory failure, and acute exacerbations in idiopathic pulmonary fibrosis, without reference to cholesterol, lifestyle-based cholesterol management, or blood pressure outcomes.",
          "pmid": "35752506",
          "title": "[French practical guidelines for the diagnosis and management of IPF\u00a0-\u00a02021 update, full version].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns clinical practice guidelines for idiopathic pulmonary fibrosis, addressing diagnosis, antifibrotic therapy, transplantation, symptom management, and related topics. It does not discuss cholesterol management, lifestyle interventions, blood pressure, or their interrelationship, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Guidelines cover epidemiology, diagnostic workup, imaging, biopsy, genetic testing, functional evaluation, antifibrotic therapy, lung transplantation, symptom management, comorbidities, chronic respiratory failure, and acute exacerbations in idiopathic pulmonary fibrosis; no mention of cholesterol, lifestyle-based cholesterol management, or blood pressure effects.",
          "pmid": "35304014",
          "title": "[French practical guidelines for the diagnosis and management of IPF\u00a0-\u00a02021 update, short version].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses maternal deaths due to hypertensive disorders in pregnancy, focusing on obstetric, anesthetic, and intensive care management failures. It does not mention cholesterol levels, lifestyle-based cholesterol management, or blood pressure modulation via lifestyle, nor does it compare outcomes independent of drug therapy. Therefore it neither supports nor conflicts with the proposed behavioral mechanism.",
          "key_findings": "Six maternal deaths in France (2013\u20132015) were due to hypertensive disorders; all occurred postpartum. Most involved cesarean delivery, some had DIC, and care was judged non-optimal in all cases, with suboptimal prenatal, obstetric, anesthetic, and intensive care. The paper emphasizes preventable deaths and improved management of eclampsia (magnesium sulfate) and HELLP/DIC recognition, without any discussion of cholesterol or lifestyle-based blood pressure management.",
          "pmid": "33161188",
          "title": "[Maternal deaths due to hypertensive disorders in France 2013-2015].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports cross-sectional prevalence of metabolic syndrome components (including blood pressure and HDL cholesterol) in antipsychotic-na\u00efve patients at risk of psychosis versus a population cohort. It does not examine lifestyle-based cholesterol management, any intervention, or whether changes in cholesterol via lifestyle alter blood pressure independent of drugs. The mention of HDL cholesterol and blood pressure is observational, not mechanistic or interventional.",
          "key_findings": "In unmedicated, antipsychotic-na\u00efve clinical high-risk psychosis patients versus a large control sample, there was slightly higher prevalence of elevated blood pressure (35.0% vs. 28.0%), increased waist circumference (17.6% vs. 15.1%), and increased fasting blood glucose (9.4% vs. 4.0%). Reduced HDL cholesterol concentrations were more common in the CHR group (20.2% vs. 13.3%). No data on lifestyle-based cholesterol management or its independent effect on blood pressure were provided.",
          "pmid": "27751654",
          "title": "Prevalence of metabolic syndrome in female and male patients at risk of psychosis.",
          "analysis_method": "llm"
        }
      ]
    }
  ]
}